documents incorporated reference portions definitive proxy statement registrants annual meeting shareholders filed within days conclusion registrant 's fiscal year ended december us securities exchange commission pursuant regulation securities exchange act amended incorporated reference part iii annual report extent described thereinbristolmyers squibb company index december part item business acquisitions divestitures products intellectual property product exclusivity research development alliances marketing distribution customers competition pricing price constraints market access government regulation sources availability raw materials manufacturing quality assurance environmental regulation employees foreign operations bristolmyers squibb website item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ia executive officers registrant part ii item market registrant 's common stock stockholder matters item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data consolidated statements earnings comprehensive income consolidated balance sheets consolidated statements cash flows notes financial statements item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item auditor fees part iv item exhibits financial statement schedule item summary signatures summary abbreviated terms exhibit index indicates brand names products trademarks owned bms specific trademark ownership information included exhibit index end form kpart item business general bristolmyers squibb company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis refer summary abbreviated terms end terms used throughout document operate one segmentbiopharmaceuticals additional information business segments refer item financial statements supplementary datanote accounting policies recently issued accounting standards principal strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry focus specialty biopharmaceutical company discovering developing delivering transformational medicines patients facing serious diseases four strategic priorities drive business performance continue build leading franchise io maintain diversified portfolio within outside io continue disciplined approach capital allocation including establishing partnerships collaborations inlicensing acquiring investigational compounds essential component successfully delivering transformational medicines patients expect planned acquisition celgene announced january enable us create leading focused specialty biopharmaceutical company well positioned address needs patients cancer inflammatory immunologic cardiovascular diseases highvalue innovative medicines leading scientific capabilities plan remain focused broadening portfolio marketed medicines pipeline assets complementary disease areas combined company operate global reach scale speed agility core company 's strategic approach discussion strategy initiatives see item management 's discussion analysis financial condition results operationsstrategy compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products us puerto rico four foreign countries revenues come products following therapeutic classes oncology cardiovascular immunoscience percentage revenues significant regioncountry follows year ended december dollars millions united states europe rest world total revenues acquisitions divestitures licensing arrangements acquisitions divestitures licensing arrangements allow us focus resources behind growth opportunities drive greatest longterm value january announced entered definitive merger agreement celgene acquire celgene discussion pending acquisition celgene acquisitions divestitures licensing arrangements refer item risk factors item financial statements supplementary datanote acquisitions divestitures licensing arrangements note subsequent event products intellectual property product exclusivity pharmaceutical products include chemicallysynthesized small molecule drugs products produced biological processes called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections intravenous infusion product summary including approved indications information alliance arrangements products refer alliances item financial statements supplementary datanote alliances opdivo opdivo nivolumab biological product fully human monoclonal antibody binds pd nkt cells opdivo received approvals several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen also approved multiple markets treatment melanoma rcc crc several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents eliquis eliquis apixaban oral factor xa inhibitor targeted stroke prevention adult patients nvaf prevention treatment vte disorders orencia orencia abatacept biological product fusion protein indicated adult patients moderately severely active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment patients philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate treatment children adolescents aged year years chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable metastatic melanoma empliciti empliciti elotuzumab biological product humanized monoclonal antibody treatment multiple myeloma baraclude baraclude entecavir oral antiviral agent treatment chronic hepatitis b reyataz franchise reyataz atazanavir sulfate franchise includes reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy containing reyataz tybost cobicistat sustiva franchise sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced rdp exclusivity rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries rdp exclusivity rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives provide market exclusivity period product expires beyond patent term us eu japan provide rdp period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy certain markets patent protection forms market exclusivity may expired rdp particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration rdp exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion impact generic competition business refer competition specific aspects law governing market exclusivity data regulatory protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term due regulatory review periods innovator may depending number factors apply government restore lost patent term extending expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical product company files nda medicine biological product bla filed type application filed affects rdp exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical studies conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types rdp innovative chemical pharmaceutical product entitled five years rdp us fda approve generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear rdp period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical studies may receive three years rdp formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar version may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file maa product health authorities maa approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan also sell pharmaceutical products countries however data provided country bycountry basis individual country revenues significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical study data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate generally estimated loe table pertains rdp composition matter com patent expiration respective products patent term restoration ptr granted estimated loe us eua japan prioritized brands opdivo nivolumab eliquis apixaban orencia abatacept b sprycel dasatinib c yervoy ipilimumab empliciti elotuzumab established brands reyataz atazanavir sulfate franchise expired hepatitis c franchise december epo 's opposition division upheld validity patent directed use dasatinib treat cml expires refer item financial statements supplementary datanote legal proceedings contingencies information eu countries granted ptr loe based com patent rdp expiry opdivo eliquis yervoy empliciti b bms aware orencia biosimilar market us eu japan us eu estimated loe dates based method use patents expires formulation additional patents expire beyond c bms entered settlement agreement apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate anda product september earlier certain circumstances hepatitis c franchise relates products containing daclatasvir loe dates us eu reflect pending ptrs research development rd critical longterm competitiveness concentrate rd efforts following disease areas significant unmet medical needs oncology including io immunoscience priorities psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priorities lung ipf liver nash also continue analyze may selectively pursue promising leads areas rd pipeline includes potential medicines various modalities mostly small chemically manufactured molecules large protein moleculesalso known biologicsbut also include millamolecules antibody drug conjugates gene therapies addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug typically includes phase phase ii phase iii clinical studies designed specifically support nda particular indication assuming studies successful phase clinical studies involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical studies involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical studies conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate although regulatory approval typically based results phase iii clinical studies times approval granted based data earlier studies consider registrational studies significant rd programs programs may include investigational compounds phases ii iii development initial indications marketed products development additional indications formulations expanding currently marketed products particularly opdivo combination yervoy agents first secondline therapy new indications substantial portion rd program strategy drug development time consuming expensive risky rd process typically takes fourteen years approximately two half years often spent phase iii latestage development average one molecules discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately small molecules enter phase development fail achieve regulatory approval small molecules enter phase ii development failure rate approximately approximately fail phase iii development biologics failure rate approximately phase development approximately phase ii development approximately phase iii development total rd expenses include costs discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support marketed products proportionate allocations enterprisewide costs upfront contingent milestone payments licensing acquiring assets rd expenses billion billion billion including license asset acquisition charges approximately billion million end employed approximately people rd related support activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs product portfolio basis investing resources stage rd early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses last three years opdivo individual investigational compound marketed product represent rd expenses last three years part operating model evolution rd geographic footprint significantly transform foster speed innovation future transformation involves closing hopewell new jersey wallingford connecticut rd sites accompanied additional investment expansion opening others example expanding lawrenceville new jersey redwood city california sites opened new rd facility cambridge massachusetts supplement internal drug discovery development programs alliances collaborative agreements help us bring new molecular agents capabilities platforms pipeline management continues emphasize leadership innovation productivity quality strategies success rd activities listed investigational compounds clinical studies well approved potential indications marketed products related therapeutic area january whether listed compounds ultimately becomes marketed product depends results clinical studies competitive landscape potential products market reimbursement decisions payers manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound gets approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds oncology phase phase ii phase iii approved indications opdivo opdivo opdivo opdivo solid tumors l crc l glioblastoma l braf wildtype metastatic hematologic malignancies nonhodgkin lymphoma diffuse l hcc melanoma opdivo yervoy large bcell lymphoma l head neck adjuvant melanoma solid tumors nonhodgkin lymphoma follicular l head neck locally advanced hodgkin lymphoma relatlimab lymphoma advanced melanoma across braf status solid tumors ovarian l esophageal mesothelioma hematologic malignancies pan tumor tmb high adjuvant bladder previously treated advanced nlrp agonist pediatric adjuvant rcc solid tumors primary testicular lymphoma esophagealgastroesophageal previously treated gastric antitim opdivo adjuvant gastric cancer jpn solid tumors solid tumors adjuvant hcc previously treated hcc humaxil opdivo yervoy adjuvant rcc previously treated metastatic head neck solid tumors prostate nsclc neoadjuvant previously treated metastatic ep antagonist opdivo yervoy refractory hodgkin melanoma solid tumors solid tumors lymphoma previously treated metastatic cdcd oncolytic relatlimab opdivo unresectable nsclc msihigh crc virus solid tumors opdivo yervoy previously treated metastatic solid tumors ido opdivo l bladder nonsquamous nsclc antictla probody solid tumors l esophageal previously treated metastatic solid tumors nktr opdivo l gastric squamous nsclc antiicos solid tumors l head neck previously treated metastatic sclc solid tumors ccr dual antagonist l mesothelioma previously treated metastatic antictla nf solid tumors l nsclc urothelial solid tumors cabiralizumab l sclc opdivo yervoy antitigit solid tumors adjuvant melanoma l rcc solid tumors adjuvant rcc braf wildtype metastatic anticd nsclc egfr mutant melanoma solid tumors opdivo yervoy melanoma across braf status cabozantinib bet inhibitor previously treated metastatic metastatic rcc solid tumors msihigh crc opdivo empliciti ulocuplumab yervoy multiple myeloma hematologic malignancies adjuvant melanoma opdivo ido adolescent metastatic l metastatic melanoma melanoma neoadjuvant muscleinvasive metastatic melanoma bladder cancer empliciti opdivo nktr relapsedrefractory multiple l melanoma myeloma pomalyst combo l rcc relapsedrefractory multiple relatlimab opdivo myeloma revlimid combo l melanoma sprycel empliciti l cml l multiple myeloma pediatric revlimid combo refractory cml note pipeline excludes clinical collaborations development partnership opdivo yervoy relatlimab ep ono collaboration ono also includes early stage compounds empliciti abbvie nktr nektar cabiralizumab five prime cabozantinib exelixis trials exploring various combinations partnerrun study immunoscience phase phase ii phase iii approved indications rort tyk inhibitor orencia orencia autoimmune disease autoimmune diseases idiopathic inflammatory early ra sp agonist btk inhibitor myopathy jia intravenous autoimmune disease ra sjgrens disease jia subcutaneous btk max tyk inhibitor psoriatic arthritis ra psoriasis ra auto injector tyk inhibitor nulojix ra intravenous switch calcineurin autoimmune disease ra subcutaneous inhibitor renal transplant tlr antagonist nulojix autoimmune disease de novo renal transplant cardiovascular phase phase ii phase iii approved indications fpr agonist nitroxyl donor eliquis eliquis heart failure heart failure pediatric venous stroke prevention atrial fibrillation apj agonist factor xia inhibitor thromboembolism prevention venous thromboembolism prevention orthopedic surgery heart failure thrombosis venous thromboembolism treatment eliquis pediatric heart disease fibrotic diseases phase phase ii lpa antagonist hsp fibrosis fibrosis pegbelfermin peg fgf nonalcoholic steatohepatitis note pipeline excludes clinical collaborations development partnership eliquis pfizer factor xia inhibitor janssen hsp nitto denko january following potential registrational study readouts opdivo anticipated tumor study details tumor study details cm opdivo yervoy st line part cm opdivo chemo st line bladder cancer cm opdivo yervoy st line part b cm opdivo adjuvant nonsmall cell lung cm opdivo chemo st line part cm opdivo yervoy chemo st line esophageal cancer cancer cmla opdivo yervoy chemo st line cm opdivo adjuvant cm opdivo yervoy egfr tm mutant renal cancer cmer opdivo chemo st line cm opdivo chemo neoadjuvant cm opdivo chemo st line methylated hepatocellular glioblastoma cm opdivo chemo st line unmethylated carcinoma cm opdivo st line cm opdivo yervoy st line mesothelioma cm opdivo yervoy st line head neck cancer cm opdivo yervoy st line melanoma cm opdivo yervoy adjuvant phase ii phase iii alliances enter alliances third parties transfer rights develop manufacture market andor sell pharmaceutical products alliances include licensing codevelopment cocommercial arrangements well joint ventures alliances involve sharing research development costs overall investment risk bms compounds lead revenuegenerating products reduced however profitability alliance products generally lower profits alliance products shared alliance partners via profit sharing royalties actively pursue arrangements view alliances important complement discovery development commercialization activities alliance arrangements contain customary early termination provisions following material breaches bankruptcy product safety concerns arrangements also typically provide termination bms without cause amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination notice period generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured bms terminates without cause sometimes bms 's right terminate without cause may exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance typically retain rights another party 's product intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations loss cash flows caused loss rights could material financial condition liquidity alliance agreements may structured terminate specific dates upon product 's patent expiration date without expiry date profit sharing payments typically expiration date royalty payments cease upon loe including patent expiration refer item financial statements supplementary datanote alliances information significant alliance agreements well alliance agreements marketing distribution customers promote appropriate use products directly healthcare professionals organizations doctors nurse practitioners physician assistants pharmacists technologists hospitals pbms mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals refer government regulation field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information potential additional uses products provide information scientific exchange scientific congresses share information products appropriate ways including development publications response unsolicited inquiries doctors medical professionals mcos operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new approved products uses well approved uses established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers specialty distributors lesser extent directly distributors retailers hospitals clinics government agencies pharmacies refer item financial statements supplementary datanote revenue gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues us business dsas substantially direct wholesaler distributor customers allow us monitor us wholesaler distributor inventory levels requires wholesalers distributors maintain inventory levels one month demand dsas including three largest wholesalers expire december subject certain termination provisions nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting reliably gather report inventory levels customers number countries outside us contract distributors support certain products services provided distributors vary market may include distribution logistics regulatory pharmacovigilance andor sales advertising promotion sales distributorbased countries represented approximately companys total revenues competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service rd new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales advancements treating cancer io therapies continue evolve rapid pace io products particularly opdivo operate highly competitive marketplace addition competing market share io products approved indications lung cancer melanoma face increased competition existing competing io products receive fda approval additional indications new io agents receive fda approval enter market furthermore therapies combining different io products io products existing chemotherapy targeted therapy treatments investigated potential expanded approvals anticipate io products continue experience intense competition another competitive challenge face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical studies demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less rd researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion product 's revenue short period time expiration exclusivity rate revenue decline product varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenue decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity refer products intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs along ability manufacture products efficiently market effectively highly competitive environment pricing price constraints market access medicines priced based number factors including value scientific innovation patients society context overall health care spend economic factors impacting health care systems ability provide appropriate sustainable access necessity sustain investment innovation platforms address serious unmet medical needs central price clinical value innovation brings market current landscape alternative treatment options goals ensuring appropriate patient access innovation sustaining investment creative platforms continue explore new pricing approaches ensure patients access medicines enhancing patient access medicines priority us focused offering creative tiered pricing voluntary licensing reimbursement support patient assistance programs optimize access protecting innovation advocating sustainable healthcare policies infrastructure leveraging advocacypayers input utilizing partnerships appropriate improving access care supportive services vulnerable patients partnerships demonstration projects important factor pricing medicines depends government regulation subject increasing international domestic efforts various governments implement strengthen measures regulate pharmaceutical market access product pricing payment operate globally countries robust governmentmandated cost containment programs efforts control costs manage use products remain strong certain markets outside us us required provide discounted pricing rebates federal government respective state governments purchases pharmaceutical products various federal state healthcare programs federal government officials legislators continue face intense pressure public manage perceived high cost pharmaceuticals responded pursuing legislation rules would reduce cost drugs federal government pays also monitoring efforts states including laws recently enacted california vermont nevada new york focused providing drug pricing transparency seeking additional rebates limiting state spending drugs international federal state legislative regulatory developments could create new constraints ability set prices andor impact market access certain areas discussion pricing pressure risk refer item risk factors growth mcos us optum uhc silver scripts cvs express scripts esi also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators health maintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical studies demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies many markets outside us operate environment governmentmandated costcontainment programs markets significant portion funding healthcare services determination pricing reimbursement pharmaceutical products subject either direct government control point care governments significant power large single payers result products may face restricted access public private payers may subject assessments comparative value effectiveness competitive products several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts rebate schemes methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing eu markets germany government set pricing restrictions launch pricing freedom subsequently limited companies may also face significant delays market access new products mainly france spain italy belgium year elapse new medicines become available patients market additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals volume discounts cost caps cost sharing increases excess prior year costs individual products aggregated market level spending outcomebased pricing schemes free products portion expected therapy period recent years italy example imposed mandatory price decreases clawback rebate structure existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows government regulation pharmaceutical industry subject extensive global regulations regional country state local agencies federal food drug cosmetic act federal statutes regulations various state statutes regulations including newly enacted state laws regulating drug price transparency rebates drug spending laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments fda particular importance us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us regulatory review process resource intensive undertaking fda pharmaceutical manufacturer improvements efficiency process significant impact bringing new therapies patients quickly fda employ several tools expedite certain applications including fast track designation accelerated approval others recently fda oncology center excellence oce established two new pilot projects test novel approaches regulatory review oncology drugs realtime oncology review rtor assessment aid aaid aaid pilot program fda approved empliciti november additional multiple myeloma indication combination pomalidomide dexamethasone treatment adult patients received least two prior therapies including lenalidomide proteasome inhibitor approval achieved weeks priority review prescription drug user fee act pdufa date fda mandates drugs manufactured packaged labeled conformity cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject pdma part federal food drug cosmetic act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain safety related drug labeling changes mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical studies prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement administration procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases result hr reconciliation bill containing package changes healthcare bill continue experience additional financial costs certain changes business example minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act required provide discount rising thereafter brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded drug sales certain government programs including medicare medicaid department veterans affairs department defense tricare amount annual fee imposed pharmaceutical manufacturers whole billion billion fee decrease billion thereafter activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda ec approval obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country discussion rebates programs refer item managements discussion analysis financial condition results operations gtn adjustments critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing refer manufacturing quality assurance discussions particular products manufacturing quality assurance operate manage manufacturing network manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant pharmaceutical manufacturing facilities located us puerto rico ireland france italy require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product portfolio continues evolve expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multi product bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility startup phase new largescale biologics manufacturing facility cruiserath ireland expected approved commercial use early rely third parties manufacture supply us portion active product ingredient drug substance necessary us manufacture various products opdivo eliquis orencia sprycel yervoy baraclude reyataz sustiva franchise continue shift towards using thirdparty manufacturers supply established brands maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted certain supply arrangements extend multiple years committed amounts using expected near longterm demand requirements subject change additional protection cases take steps maintain approved back source available example capability manufacture opdivo internally also arrangements thirdparty manufacturers meet demand connection acquisitions divestitures licensing collaboration arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties intend continue enter agreements future addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain records demonstrate quality integrity technical information production processes control production processes involves established specifications standards ingredients equipment facilities manufacturing methods operations packaging materials labeling perform tests various stages production processes final product product samples held stability ensure product meets regulatory requirements conforms standards tests may involve chemical physical analyses microbiological testing combination along analyses quality control testing provided business unitsite thirdparty laboratories quality assurance groups routinely monitor manufacturing procedures systems used us subsidiaries thirdparty suppliers assure quality compliance requirements met environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis material addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters refer item financial statements supplementary datanote legal proceedings contingencies employees approximately employees december foreign operations significant operations outside us conducted subsidiaries distributors international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act documents also available secs website wwwsecgov information relating corporate governance bristolmyers squibb including principles integrity code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website usour company leadership investors captions print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsshareholder services caption addition information sustainability programs available website ussustainability caption foregoing information regarding website content convenience information contained connected website deemed incorporated reference filed sec incorporate reference certain information parts definitive proxy statement annual meeting shareholders proxy statement sec allows us disclose important information referring manner please refer information proxy statement available website investorssec filings caption within days end fiscal year item risk factors risks uncertainties described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial could also impair business operations financial condition following discussion risk factors contains forwardlooking statements discussed item managements discussion analysis financial condition results operationsspecial note regarding forwardlooking statements also face certain risks connection proposed acquisition celgene described item encourage consider risks caption risks related proposed acquisition celgene risk factors set forth registration statement form registration initially filed sec february subsequently amended february february additional risk factors relating proposed acquisition celgene risks related business public announcement data clinical studies competitors news developments related competitors ' products latestage compounds may cause significant volatility stock price depending data may result adverse impact business financial condition results operations development key io compounds whether alone part combination therapy delayed discontinued clinical study meet one primary endpoints stock price could decline significantly may adverse impact business financial condition results operations focusing efforts resources disease areas high unmet need focused portfolio investors placing heightened scrutiny products latestage compounds particular opdivo backbone io portfolio announced multiple regulatory milestones opdivo resulted label expansions new indications however also experienced setbacks may continue developments clinical studies expect receive data ongoing clinical studies including information checkmate combination study firstline lung cancer setting decisions health authorities regarding potential label expansions announcement data clinical studies competitors news developments related competitors ' products late stage compounds opdivo may cause significant volatility stock price depending news may result adverse impact business financial condition results operations furthermore announcement negative unexpected data discontinuation development key io compounds whether alone part combination therapy delay anticipated timelines filing regulatory approval significant advancement competitor may cause stock price decline significantly may adverse impact business financial condition results operations assurance data clinical studies support filings regulatory approval key io compounds may prove effective effective competing compounds even approved key io compounds become commercially successful approved indications depend several key products revenues cash flows earnings derive majority revenue earnings several key products six prioritized brands comprised approximately revenues growth products opdivo eliquis represented expected increasingly represent significant part revenue earnings cash flows reduction revenue products could adversely impact earnings cash flows also one major products become subject issues loss patent protection significant changes demand formulary access changes material product liability unexpected side effects regulatory proceedings negative publicity supply disruption manufacturing operations thirdparty supplier significant advancement competing products may incur adverse impact business financial condition results operations trading price stock may experience difficulties delays development commercialization new products compounds products may appear promising development fail reach market within expected optimal timeframe addition product extensions additional indications may approved furthermore products indications approved us fda 's accelerated approval program may contingent upon verification description clinical benefit confirmatory studies studies may successful example november announced checkmate study meet primary endpoint overall survival opdivoyervoy versus placebo maintenance therapy patients extensivestage sclc completion firstline platinumbased chemotherapy developing commercializing new compounds products include inherent risks uncertainties including due efficacy safety concerns delayed denied regulatory approvals delays challenges producing products commercial scale excessive costs manufacture ii failure enter implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs canceled believe commercial prospects reduced may recognize material noncash impairment charges programs finally losing key molecules intermediaries compound library natural manmade disaster act sabotage could negatively impact product development cycle face intense competition manufacturers bms dependent market access uptake expansion marketed brands new product introductions new indications product extensions co promotional activities alliance partners deliver future growth competition keen includes lowerpriced generics increasingly aggressive generic commercialization tactics ii new competitive products entering market particularly io iii lower prices companies ' products real perceived superior efficacy benefit safety risk profiles differentiating factors iv technological advances patents attained competitors v clinical study results products competitors products affect value proposition products vi business combinations among competitors major thirdparty payers vii competing interests external partnerships develop bring new products markets unable compete successfully competitors ' products marketplace could material negative impact revenues earnings could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file countries addition patent environment unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions approved marketed generic biosimilar product manufacturers well groups seeking financial gain also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject patent litigation example february one eu patents sprycel revoked opposition division epo may experience decline european revenues upon entry generics market refer item financial statements supplementary datanote legal proceedings contingencies information cases manufacturers may seek regulatory approval submitting clinical study data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation assurance particular product enjoy market exclusivity full time period appears estimates disclosed assume provide financial guidance addition countries india allowing competitors manufacture sell competing generic products negatively impacts protections afforded company lowerpriced biosimilars bms biologic products competing biologics could negatively impact volumes prices litigation claiming infringement intellectual property may adversely affect future revenues operating earnings third parties may claim infringe upon intellectual property resolving intellectual property infringement claim costly time consuming may require us enter license agreements may available commercially reasonable terms successful claim patent intellectual property infringement could subject us significant damages injunction preventing manufacture sale use affected product products events could material adverse effect profitability financial condition addition proposed celgene acquisition consummated also subject certain intellectual property claims celgene adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii antibribery regulations us foreign corrupt practice act uk bribery act including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws viii environmental health safety sustainability matters ix tax liabilities resulting assessments tax authorities increased pricing pressure restrictions us abroad mcos institutional purchasers government agencies programs among others could negatively affect revenues profit margins products continue subject increasing pressures across portfolio market access pricing discounting restrictions us eu regions around world including rules practices mcos institutional governmental purchasers ii government administrative policy changes changes laws regulations federal healthcare programs medicare medicaid government actions inquiries federal level including proposals contained american patient first blueprint seek amend pharmaceutical pricing rebate reimbursement practices using international pricing indexes modifying federal antikickback statute discount safe harbor accelerating generic drug approval processes promoting use biosimilar drugs option applying step therapy listing prices products advertising granting additional authority governmental agencies manage drug utilization negotiate drug prices laws state level recently enacted california vermont nevada new york focused drug pricing transparency andor limiting state spending drugs iii potential impact changes pharmaceutical reimbursement changes resulting implementation guidance final rule issued centers medicare medicaid services cms calculation average manufacturer price best price changes required based guidance cms rule deferred iv impact increased pricing pressure medicare part formularies medicare part b reimbursement rates physicians expanded utilization b drug pricing program well commercial formularies general v reimbursement delays vi government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing vii collection delays failures pay governmentfunded public hospitals outside us viii impact pricing parallel trade drug importation across borders ix developments technology andor industry practices could impact reimbursement policies practices third party payers x inhibited market access due real perceived differences value propositions products compared competing products subject variety us international laws regulations currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business operating results financial condition company include additional healthcare reform initiatives us countries including additional mandatory discounts fees ii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iii changes intellectual property law iv changes accounting standards v new increasing data privacy regulations enforcement particularly eu us vi emerging new global regulatory requirements reporting payments value transfers healthcare professionals vii potential impact importation restrictions legislative andor regulatory changes changes tax regulations could negatively impact earnings subject income taxes us various countries globally particular although passage tax cuts jobs act reduced us tax rate future earnings could negatively impacted changes tax legislation including changing tax rates tax base limiting phasingout eliminating deductions tax credits taxing certain excess income intellectual property changing rules earnings repatriations changing tax laws us countries thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent significant percentage pretax income including royalties related divestiture plavix avaproavalide erbitux diabetes businesses including transfer certain future royalty rights pertaining amylin onglyza farxiga product sales sanofi arrangement outlicensed intellectual property merck patent infringement settlement pretax income generated royalties approximately billion pretax income could adversely affected royalty streams decline future periods failure third parties meet contractual regulatory obligations could adversely affect business rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance business unit functional services meet contractual regulatory obligations using third parties poses number risks may perform standards legal requirements example relation outsourcing significant clinical development activities innovative medicines contract research organizations ii may produce reliable results iii may perform timely manner iv may maintain confidentiality proprietary information v may incur significant cyberattack business disruption vi disputes may arise respect ownership rights technology developed partners vii disagreements could cause delays termination research development commercialization product result litigation arbitration moreover third parties located markets subject political social risk corruption infrastructure problems natural disasters addition country specific privacy data security risk given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences failure execute business strategy could adversely impact growth profitability strategy focused delivering innovative transformational medicines patients focused set disease areas unable successfully execute strategy could negatively impact future results operations market capitalization connection strategy process acquiring celgene leading innovative biotech company complements existing portfolio medicines pipeline assets across key disease areas focus ability successfully complete acquisition successfully integrate celgene could impact results operations able achieve cost savings expect could negatively impact operating margin earnings results addition may unable consistently maintain adequate pipeline internal rd programs transactions third parties support future revenue growth competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change operating model evolution manage costs effectively operating results financial condition could negatively impacted failure attract retain highly qualified personnel could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical rd governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel costs materially increase businesses assets acquire future may underperform may able successfully integrate existing business occurrence number unexpected factors could prevent substantially delay consummation anticipated acquisition divestiture merger acquired inlicensed number assets expect continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due low product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii tax considerations addition due substantial amount debt expect incur finance cash portion proposed celgene acquisition consideration assurance acquisition consummated choose continue invest technologies could experience difficulties delays manufacturing distribution sale products product supply related patient access could negatively impacted among things product seizures recalls forced closings manufacturing plants ii failure failure suppliers comply cgmp applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods within reasonable timeframe required quality v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products opdivo vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity changes types products produced biologics physical limitations business interruptions ix disruption supply chain continuity including natural disasters acts war terrorism external factors control impacting one facilities critical supplier example new biologics manufacturing facility cruiserath ireland expected approved commercial use early delay planned opening site could impact supply products require us obtain product supply third parties significant cost product labeling changes marketed products could result negative impact revenues profit margins regulatory authorities may need change labeling pharmaceutical product including product marketed several years changes often result additional data postmarketing studies headtohead studies adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies postmarketing experience produce important additional information product new information added products label affect riskbenefit profile leading potential recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions mcos scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact revenues due inventory returns limited patient population going forward additionally certain study results especially headtohead studies could affect products formulary listing could also adversely affect revenues illegal distribution sale third parties counterfeit unregistered versions products stolen products could negative impact revenues earnings reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business addition diversion products authorized market channels may result reduced revenues negatively affect profitability dependent information technology systems infrastructure face certain risks including cybersecurity breaches data leakage rely extensively systems networks services including internet sites data hosting processing facilities tools physical security systems hardware software technical applications platforms managed hosted provided andor used thirdparties vendors assist conducting business significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored thirdparty providers ' systems portable media storage devices could also experience business interruption theft confidential information reputational damage industrial espionage attacks malware cyberattacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue cybersecurity threats rapidly evolving sophistication becoming prevalent industry invested industry appropriate protections monitoring practices data reduce risks continue monitor systems ongoing basis current potential threats maintain cyber insurance insurance may however sufficient cover financial legal business reputational losses may result interruption breach systems assurance continuing efforts prevent breakdowns breaches thirdparty providers databases systems could adversely affect business adverse changes us global economic political conditions could adversely affect profitability global economic political risks pose significant challenges companys growth profitability difficult mitigate generated approximately revenues outside us revenues earnings cash flow exposed risk strengthening us dollar exposure customer credit risks europe south america markets including governmentguaranteed hospital receivables markets payments received time significant operations europe including manufacturing distribution results operations could negatively impacted member country exiting eurozone monetary union eu including planned exit uk eu particular exit without withdrawal agreement associated transition period place may impact research commercial general business operations uk eu including approval supply products addition discontinuation modification libor future initiatives regulate reform change manner administration benchmarks could result adverse consequences return value market securities instruments whose returns linked benchmark additionally future pension plan funding requirements continue sensitive global economic conditions related impact equity markets also disruptions credit markets downgrade current credit rating could increase future borrowing costs impair ability access capital credit markets terms commercially acceptable us could adversely affect liquidity capital resources significantly increase cost capital finally business operations may adversely affected political volatility conflicts crises individual countries regions including terrorist activities war guarantee pay dividends repurchase stock declaration amount timing dividends fall within discretion board directors board 's decision depend many factors including financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board may deem relevant reduction elimination dividend payments dividend program could adversely affect stock price addition could time decide buy back shares market could also adversely affect stock price increased use social media platforms present risks challenges increasing use social media communicate company news events inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others external media channels could lead information loss identifying new points entry social media continues expand presents new challenges risks related proposed acquisition celgene may realize anticipated benefits synergies proposed acquisition celgene january announced entered definitive merger agreement celgene acquire celgene celgene continue operate independently completion acquisition success acquisition depend part ability realize anticipated benefits successfully combining celgenes businesses plan devoting substantial management attention resources integrating business practices operations celgenes fully realize anticipated benefits acquisition nonetheless difficulties may arise process combining operations companies could result failure achieve synergies free cash flow anticipate loss key employees may difficult replace competitive pharmaceutical field disruption companys ongoing businesses inconsistencies standards controls procedures policies adversely affect ability maintain relationships customers suppliers distributors alliance partners creditors clinical trial investigators managers clinical trials result anticipated benefits acquisition may realized fully within expected timeframe may take longer realize cost expected could materially impact business cash flow financial condition results operations well adversely impact price shares combined company addition times attention certain members companys management companys resources may focused completion merger integration businesses two companies diverted daytoday business operations may disrupt companys ongoing business business combined company celgene targets securities class action derivative lawsuit connection acquisition described item financial statements supplementary datanote legal proceedings contingencies could become targets additional actions lawsuits could result substantial costs may delay prevent acquisition completed failure complete pending acquisition celgene could negatively impact stock price future business financial results obligations obligations celgene complete merger subject satisfaction waiver number conditions assurance conditions completion acquisition satisfied waived acquisition completed acquisition consummated reason may receive negative reactions shareholders providers vendors regulators employees may subjected various material risks including possibility price common stock securities may decline extent current market prices reflect market assumption acquisition completed also event termination merger agreement certain specified circumstances could required reimburse expenses celgene pay celgene termination fee billion could subject litigation related failure complete merger specifically enforce obligation perform obligations merger agreement addition merger agreement places certain restrictions conduct businesses prior completion merger restrictions waiver subject consent celgene may prevent us making certain acquisitions taking certain specified actions otherwise pursuing business opportunities pendency merger would made taken pursued restrictions place risks materialize may materially adversely affect businesses financial condition financial results ratings stock prices andor bond prices incur significant additional indebtedness finance pending acquisition celgene well transaction acquisitionrelated costs connection acquisition limit operating flexibility upon completion acquisition increase indebtedness include acquisition debt financing approximately billion assumption approximately billion celgenes debt resulting us higher debttoequity ratio addition celgene shareholders also receive one tradeable contingent value right share celgene representing right receive cash upon achievement future regulatory milestones result acquisition increased indebtedness anticipate corporate credit ratings decreased one ratings agencies increased indebtedness payments pursuant contingent value right significantly reduce amount cash flow available fund efforts combine business celgene realize expected benefits pending acquisition pursue acquisitions engage investments product development capital expenditures dividend payments share repurchases activities could among things limit flexibility planning reacting changes challenges relating business industry together decrease credit ratings increase borrowing costs addition certain circumstances could required repurchase celgenes outstanding debt securities provide assurances would sufficient funds expect incur number nonrecurring costs connection acquisition whether acquisition completed mostly comprised transaction costs facilities systems consolidation costs employmentrelated costs although expect realization efficiencies related integration businesses offset least portion costs net benefit may accomplished near term celgene may difficulty attracting motivating retaining executives key employees light proposed acquisition due specialized scientific managerial nature business celgene rely heavily ability attract retain qualified scientific technical managerial personnel competition qualified personnel pharmaceutical field intense success transaction depend part ability retain scientific technical personnel key employees celgene uncertainty effect merger celgene employees may adverse effect us celgene separately consequently combined business uncertainty may impair andor celgenes ability attract retain motivate key personnel employee retention may particularly challenging pendency merger celgenes employees may experience uncertainty future roles combined business additionally celgenes officers employees may hold shares celgene common stock merger completed officers employees may entitled cash andor merger consideration respect shares celgene common stock officers employees may hold celgene stock options celgene rsus celgene psus celgene rsas subject accelerated vesting upon termination without cause andor resignation good reason following completion merger pursuant employment agreements andor agreements arrangements celgene certain key employees celgene also entitled receive severance payments upon termination without cause andor resignation good reason following completion merger agreements certain key employees celgene potentially could resign employment following specified circumstances set forth applicable agreement including adverse change title authority responsibilities compensation benefits primary office location payments individually aggregate could make retention celgene officers employees difficult furthermore celgenes key employees depart risk departing including issues relating uncertainty difficulty integration financial security desire become employees combined business may incur significant costs retaining individuals identifying hiring retaining replacements departing employees may lose significant expertise talent relating business celgene ability realize anticipated benefits merger may materially adversely affected accordingly assurance given able attract retain key employees celgene extent celgene able attract retain employees past pending acquisition celgene consummated stockholders ownership percentage diluted proposed acquisition consummated issue celgene shareholders shares common stock result issuance shares common stock shareholders smaller percentage combined company acquisition therefore reduced voting interest acquisition based preliminary estimates may materially change completion merger proposed acquisition expected dilutive gaap eps principally due amortization intangible assets associated celgenes currently marketed product rights well additional interest acquisition integration costs although expect transaction accretive nongaap eps unexpected factors may result lower delayed accretion even dilution eps future years combined company subject risks celgene faces addition risks faced bristolmyers squibb celgene several commercialized products well diverse early latestage pipeline includes five potential nearterm product launches consummate acquisition celgene combined company may negatively affected expiration loss patent protection commercialized products occurs upon atrisk launch manufacturer generic version products addition combined company fails obtain timely requisite regulatory approvals us internationally products development research development earlystage pipeline requires greater financial investment anticipated business cash flow financial condition results operations may harmed consummate acquisition celgene assume celgenes risks arising legal proceedings like many pharmaceutical companies current legal environment celgene involved various patent product liability consumer commercial securities environmental tax litigations claims government investigations legal proceedings arise time time ordinary course business predict certainty eventual outcome celgenes pending future legal proceedings adverse outcome matters could material business cash flow financial condition results operations item b unresolved staff comments none item properties principal executive offices located east th street th floor new york ny lease manufacturing rd administration storage distribution facilities approximately sites worldwide believe manufacturing properties combination thirdparty manufacturers good operating condition provide adequate production capacity current projected operations information manufacturing properties refer item businessmanufacturing quality assurance significant manufacturing rd locations geographic area follows december manufacturing rd united states europe total item legal proceedings information pertaining legal proceedings found item financial statements supplementary datanote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting shareholders thereafter elected oneyear term successors elected executive officers serve discretion board directors name current position age employment history past years giovanni caforio md president us pharmaceuticals chairman board chief executive officer executive vice president chief commercial officer member leadership team chief operating officer director company chief executive officer director company present chairman board chief executive officer charles bancroft chief financial officer executive vice president global services chief financial officer executive vice president present chief financial officer executive vice president global business global business operations operations member leadership team paul biondi senior vice president rd operations senior vice president strategy business head business development development present senior vice president head strategy business development member leadership team christopher boerner phd senior vice president commercial seattle genetics executive vice president chief commercial officer executive vice president seattle genetics member leadership team president head us commercial president head international markets present executive vice president chief commercial officer adam dubow vice president assistant general counsel china japan intercon region senior vice president chief compliance ethics emac region officer vice president associate general counsel research development member leadership team present senior vice president chief compliance ethics officer john e elicker senior vice president public affairs investor relations senior vice president corporate affairs investor present senior vice president corporate affairs investor relations relations member leadership team ann powell judge chief human resources officer shire pharmaceuticals senior vice president chief human resources senior vice president global human resources officer present senior vice president chief human resources officer member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel thomas j lynch md present executive vice president chief scientific officer executive vice president chief scientific officer member leadership team karen santiago vice president finance global manufacturing supply senior vice president corporate controller vice president finance us commercial global capability hub lead enabling functions finance transformation present senior vice president corporate controller louis schmukler president global product development supply senior vice president president global product present senior vice president president global product development supply development supply member leadership team paul von autenried senior vice president enterprise services chief information officer senior vice president chief information officer present senior vice president chief information officer member leadership team part ii item market registrants common stock stockholder matters bristolmyers squibb common stock traded new york stock exchange symbol bmy holders common stock number record holders common stock january number record holders based upon actual number holders registered books date based information provided eq shareowner services formerly wells fargo shareowner services transfer agent include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies equity compensation plan information information required item contained proxy statement heading items voted uponitem advisory vote approve compensation named executive officersequity compensation plan information information incorporated herein reference performance graph following graph compares cumulative total stockholders ' returns common shares cumulative total stockholders ' returns companies listed standard poor 's index composite peer group major pharmaceutical companies comprised abbvie amgen astrazeneca biogen celgene gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assumes investment december common shares sp index stock peer group companies including reinvestment dividends years ended december stock price performance following graph necessarily indicative future stock price performance bristolmyers squibb sp peer group unregistered sales equity securities use proceeds following table summarizes surrenders equity securities three months ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea programsb programsb dollars millions except per share data october november december three months ended december includes shares repurchased part publicly announced programs shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock june increased authorization repurchase common stock additional billion october board directors approved new share repurchase program authorizing repurchase additional billion common stock stock repurchase program expiration date item selected financial data following table sets forth selected historical consolidated financial information five periods indicated information read together item managements discussion analysis financial condition results operations consolidated financial statements related notes included elsewhere selected historical financial information years ended december derived audited consolidated financial statements related notes five year financial summary amounts millions except per share data income statement data total revenues net earnings net earningsloss attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesa total assets longterm debta equity includes current noncurrent portion item managements discussion analysis financial condition results operations managements discussion analysis results operations financial condition provided supplement read conjunction consolidated financial statements related notes included elsewhere enhance understanding results operations financial condition cash flows executive summary bristolmyers squibb company global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end terms used throughout document received approvals new medicines additional indications formulations currently marketed medicines major markets us eu japan china including multiple regulatory milestone achievements opdivo opdivoyervoy combinations committed investigating opdivo alone combination yervoy anticancer agents wide array tumor types including broad programs lung head neck liver kidney bladder stomach continue believe breadth depth io portfolio positions us well future new io compounds clinical development studies across different tumor types addition advanced certain nonio rd programs pipeline including tyk inhibitor treatment psoriasis autoimmune diseases factor xia inhibitor treatment thrombosis collaboration janssen pegbelfermin pegfgf treatment nash revenues increased result higher demand prioritized brands including opdivo eliquis partially offset increased competition established brands primarily hiv brands daklinza increase gaap eps primarily due tax charges attributed tax reform higher revenues items partially offset higher losses equity investments adjusting impact tax reform equity investment losses specified items nongaap eps increased primarily result higher revenues higher royalties licensing income lower effective tax rate cost savings resulting transformation initiatives continue redeployed rd areas higher priorities january announced entered definitive merger agreement celgene acquire celgene discussion pending acquisition celgene acquisitions divestitures licensing arrangements refer item risk factors item financial statements supplementary datanote acquisitions divestitures licensing arrangements note subsequent event revenues increased result higher demand prioritized brands including opdivo eliquis partially offset increased competition established brands primarily daklinza decrease gaap eps due tax charges attributed tax reform per share lesser extent higher license asset acquisition restructuring related charges lower divestiture related income items partially offset higher revenues royalties licensing income patentinfringement settlement adjusting impact tax reform specified items nongaap eps increased primarily result higher revenues partially offset product mix higher rd expenses supporting opdivo io programs highlights following table summarizes financial information year ended december dollars millions except per share data total revenues diluted earnings per share gaap nongaap nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures significant product pipeline approvals following summary significant approvals received product date approval august approval japan patients mpm progressed chemotherapy august approval japan adjuvant treatment melanoma fda approval first io treatment option patients metastatic sclc whose cancer august progressed platinumbased chemotherapy least one line therapy opdivo ec approval adjuvant treatment adult patients melanoma involvement lymph nodes july metastatic disease undergone complete resection approval china treatment locally advanced metastatic nsclc prior platinumbased june chemotherapy adult patients without egfr alk genomic tumor aberrations august approval japan opdivo plus lowdose yervoy treatment unresectable metastatic rcc fda approval opdivo plus lowdose yervoy treatment adult pediatric patients years july older msih dmmr mcrc progressed following treatment fluoropyrimidine oxaliplatin irinotecan opdivoyervoy approval japan opdivoyervoy combination previously untreated patients unresectable may melanoma fda approval opdivoyervoy combination previously untreated patients intermediate poor april risk advanced rcc approval japan intravenously administered treatment moderate severe polyarticular jia orencia february patients two years age older fda approval empliciti injection intravenous use combination pomalidomide dexamethasone empliciti november treatment adult patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor fda expanded indication sprycel include treatment pediatric patients one year age december older newly diagnosed philadelphia chromosomepositive combination chemotherapy sprycel ec expanded indication sprycel include treatment children adolescents aged year july years chronic phase philadelphia chromosomepositive cml include powder oral suspension yervoy january ec approval advanced unresectable metastatic melanoma pediatric patients years age older refer product pipeline developments developments marketed products latestage pipeline early strategy focus specialty biopharmaceutical company discovering developing delivering transformational medicines address serious unmet medical needs strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry four strategic priorities drive business performance continue build leading franchise io maintain diversified portfolio within outside io continue disciplined approach capital allocation including establishing partnerships collaborations inlicensing acquiring investigational compounds essential component successfully delivering transformational medicines patients developing new medicines following core therapeutic areas oncology priority certain tumor types immunoscience priorities psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priorities lung liver continue advance next wave innovative medicines investing significantly pipeline internally business development activities expect planned acquisition celgene position us leading biopharmaceutical company expanding oncology immunoscience portfolios several nearterm assets additional external partnerships continue invest io portfolio pursuing monotherapy combination approaches advancing next wave early assets entered several new collaboration agreements across therapeutic areas focus expanded others research develop opdivo approved investigational oncology agents combination regimens remain focused well resourced cancer development programs seek broaden use opdivo earlier lines therapy expand new tumors accelerate next wave io mechanisms develop treatment options refractory io patients beyond cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic diseases strengthen partnerships diverse group companies academic institutions new expanded research activities believe differentiated internal external focus contributes advancing pipeline potentially transformational medicines commercial model evolving revenues prioritized brands continue grow demonstrates strong execution strategy continue drive growth opdivo expanding additional indications tumor types monotherapy combination yervoy anti cancer agents eliquis continues grow leveraging best class clinical profile extensive real world data number one novel oral anticoagulant total prescriptions us building continued success prioritized brands remain strongly committed orencia sprycel operating model transformation commercial infrastructure uniquely leveraged potential growth operating model continues evolve successful focusing commercial rd manufacturing resources prioritized brands markets strengthening rd capabilities tumor biology patient selection new biomarkers delivering leaner administrative functions streamlining manufacturing network reflect importance biologics current future portfolio evolution operating model focuses maintaining disciplined approach marketing selling administrative expenses enable us deliver necessary strategic financial operational flexibility invest highest priority opportunities within portfolio looking ahead continue implement biopharma strategy driving growth prioritized brands executing product launches investing diverse innovative pipeline aided strategic business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisitions divestitures licensing collaboration arrangements acquisitions divestitures licensing collaboration arrangements allow us focus resources behind growth opportunities drive greatest long term value focused following core therapeutic areas oncology including io immunoscience cardiovascular fibrosis significant acquisitions divestitures licensing collaboration arrangements past three years summarized refer item financial statements supplementary data note alliances note acquisitions divestitures licensing arrangements information arrangements nektar bms nektar commenced worldwide license collaboration development commercialization nktr nektars investigational immunostimulatory therapy janssen bms janssen commenced worldwide collaboration development commercialization factor xia program including bmss factor xia inhibitor bms investigational anticoagulant compound studied prevention treatment major thrombotic conditions promedior bms notified promedior company would exercising warrant obtained purchase outstanding shares promedior rigel bms notified rigel pharmaceuticals inc company would discontinue participation preclinical collaboration cancer immunotherapies based rigel 's small molecule tgf beta receptor kinase inhibitors originally commenced bavarian nordic bms notified bavarian nordic company exercising option globally license commercialize prostvac bavarian nordics investigational psatargeting cancer immunotherapy arrangements ono bms acquired exclusive license develop commercialize ono onos prostaglandin e receptor antagonist treatment cancer bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology may allow rapid delivery large volume injectable medications ifm bms acquired outstanding shares ifm providing bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expanded initial strategic collaboration discover novel cancer treatment therapies include eight additional targets using cytomxs proprietary probody platform treatment cancer arrangements psioxus bms acquired exclusive worldwide rights psioxus 's ng preclinical stage armed oncolytic virus goal addressing solid tumors padlock bms acquired outstanding shares padlock providing bms full rights padlocks pad inhibitor discovery program focused development treatment approaches patients ra cormorant bms acquired outstanding shares cormorant providing bms full rights cormorant 's lead candidate humaxil monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules nitto denko bms acquired exclusive worldwide license develop commercialize nitto denko 's investigational sirna molecules targeting heat shock protein hsp vitamin containing formulations including nitto denko 's lead asset ndls currently development treatment advanced liver fibrosis option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung organ fibrosis results operations regional revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change exchangeb change exchangeb united states europe rest world othera na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period sales us revenues impacted higher demand opdivo eliquis partially offset lower demand established brands due increased competition primarily hiv brands daklinza higher growth rate us due additional indication approvals opdivo average us net selling prices unchanged chargebacks rebates discounts refer product revenues commentary additional information europe revenues impacted higher demand eliquis opdivo foreign exchange partially offset lower demand established brands due increased competition lower average net selling prices rest world revenues impacted lower demand established brands due increased competition lower average net selling prices foreign exchange partially offset higher demand opdivo eliquis us revenues impacted higher demand eliquis opdivo partially offset lower demand established brands due increased competition primarily daklinza hiv brands average us net selling prices approximately higher chargebacks rebates discounts refer product revenues commentary additional information europe revenues impacted higher demand opdivo eliquis partially offset lower demand daklinza due increased competition lower average net selling prices rest world revenues impacted lower demand established brands including daklinza due increased competition outlicensing mature brand product partially offset higher demand opdivo eliquis lower average net selling prices single country outside us contributed total revenues gtn adjustments recognize revenue net gtn adjustments described critical accounting policies activities ending reserve balances significant category gtn adjustments follows rebates chargebacks medicaid returns discounts dollars millions cash discounts medicare rebates adjustments total balance january provision related sale made current period prior period payments returns foreign currency translation balance december provision related sale made current period prior period payments returns assetsrelated liabilities heldforsale foreign currency translation balance december reconciliation gross product sales net product sales significant category gtn adjustments follows year ended december change dollars millions vs vs gross product sales gtn adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales gtn adjustments percentage us nonus gtn adjustments primarily function product sales volume regional payer channel mix contractual legislative discounts rebates gtn adjustments increasing higher rate gross product sales due higher us eliquis gross product sales relatively high gtn adjustment percentage result competitive pressures maintain position healthcare payer formularies allowing patients continued access medical plans product revenues year ended december change dollars millions vs vs prioritized brands opdivo us nonus eliquis us nonus orencia us nonus sprycel us nonus yervoy us nonus empliciti us nonus established brands baraclude us nonus reyataz franchise us nonus sustiva franchise us nonus hepatitis c franchise us nonus brands us nonus total revenues us nonus change excess opdivo nivolumab fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach continues investigated across tumor types disease areas us revenues increased periods due higher demand higher growth rate primarily due approvals treatment adjuvant melanoma liver cancer opdivoyervoy combination kidney cancer partially offset decline lung cancer indication international revenues increased periods due higher demand result approvals additional indications launches new countries lower growth rate primarily due additional competition opdivo nsclc indication eliquis apixaban oral factor xa inhibitor targeted stroke prevention adult patients nvaf prevention treatment vte disorders us revenues increased periods due market share gains partially offset lower average net selling prices international revenues increased periods due higher demand attributed market share gains growth novel oral anticoagulants market orencia abatacept fusion protein indicated adult patients moderate severe active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia us revenues increased periods due higher demand higher average net selling prices international revenues increased periods due higher demand may experience additional competition europe biosimilars competitor products future periods sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment adults philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate us revenues decreased due inventory workdown offset higher average net selling prices us revenues increased due higher demand higher average net selling prices international revenues remained unchanged international revenues increased due higher demand may experience decline european revenues event generic datasinib product enters market yervoy ipilimumab monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased periods due higher demand revenue growth rate decreased due lower demand resulting io products used adjuvant treatment patients melanoma including opdivo international revenues increased periods due higher demand primarily europe following approval opdivoyervoy combination therapy melanoma baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenues decreased periods due lower demand resulting increased competition reyataz atazanavir sulfate franchise includes reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy containing reyataz tybost cobicistat loe reyataz us occurred december result revenues continue decline international revenues decreased periods due lower demand resulting increased competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla loe sustiva us occurred december gilead terminated bms 's participation us canada joint venture following launch generic version sustiva us result bms 's share atripla revenues decline next two years refer item financial statementsnote alliances discussion international revenues include million us atripla royalty revenue hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor us international revenues decreased periods due lower demand resulting increased competition brands includes brands including lost exclusivity major markets otc brands royalty revenue international revenues decreased primarily due lower plavix royalties result adoption amended revenue guidance expiration rights abilify canada lower diabetes product supply sales continued generic erosion revenue decrease due outlicensing divestiture certain brands continued generic erosion estimated enduser demand pursuant sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated december daklinza months inventory hand us result minimum required stock levels support patient demand expect inventory hand levels daklinza exceed one month near term international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france efferalgan analgesic product sold principally europe months inventory hand internationally direct customers compared also months inventory hand june level inventory hand primarily due ordering patterns pharmacists france fervex cold flu product months inventory hand direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france daklinza hepatitis c product months inventory hand internationally direct customers compared months inventory hand june level inventory hand attributable low volume inmarket sales canada perfalgan analgesic product months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily gulf countries due extended delivery lead time sustiva hiv product months inventory hand internationally direct customers compared months inventory hand june level inventory hand attributable low volume inmarket sales canada us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers thirdparty market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative research development income net total expenses cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty product supply costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing certain excise taxes foreign currency hedge settlement gains losses amortization acquired developed technology costs cost products sold typically vary periods result product mix volume particularly royalties profit sharing lesser extent changes foreign currency price inflation costs attributed manufacturing site exits cost products sold increased due higher royalties profit sharing million resulting primarily higher eliquis sales partially offset product cost improvements million impairment charge reduce carrying value small molecule active pharmaceutical ingredient manufacturing operations swords ireland lower inventory charges cost products sold increased due higher royalties profit sharing million resulting primarily higher eliquis sales million impairment charge discussed remaining increase primarily due higher sales volume inventory charges manufacturing startup costs foreign currency marketing selling administrative marketing selling administrative expenses primarily include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods due new product launch promotional activities marketing selling administrative expenses decreased due lower advertising promotion marketing expenses lower costs attributed transformation initiatives lower branded prescription drug fee partially offset higher bms foundation grants marketing selling administrative expenses decreased due lower advertising promotion salesforce expenses supporting daklinza established brands lower bms foundation grants research development research development activities include discovery research preclinical clinical development drug formulation medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods number reasons including timing license asset acquisition charges iprd impairment charges research development expense decreased due lower site exit costs iprd impairment charges partially offset expansion opdivo io development programs including nktr research development expense increased due higher license asset acquisition charges site exit charges iprd impairment charges expansion opdivo io development programs significant charges included rd expense follows year ended december dollars millions nektar cormorant b ifm b cytomx halozyme flexus b b cardioxyl b psioxus ono padlock nitto denko license asset acquisition charges fstar iprd impairments site exit costs research development significant charges upfront payment b milestone payment license asset acquisition charges resulted strategic transactions acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compounds options acquire license disclosed acquisitions divestitures licensing collaboration arrangements iprd impairment charges includes discontinued development investigational compound part alliance fstar site exit costs resulted expected exit rd sites us primarily due reduction estimated useful lives related assets impairment charge reduce carrying value rd facility wallingford connecticut income net income net decreased primarily due losses equity investments related nektar patent infringement settlement partially offset lower restructuring debt redemption charges income net increased primarily due patent infringement settlement outlicensing income partially offset lower divestiture gains related service fees higher restructuring debt redemption charges components income net follows year ended december dollars millions interest expense investment income lossgain equity investments provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investments includes fair value adjustment million related company 's equity investment nektar restructuring charges relate changes company 's operating model drive continued success near longterm focused investment commercial opportunities key brands markets competitive agile rd organization accelerate pipeline streamline operations realign manufacturing capabilities broaden biologics capabilities reflect current future portfolio well streamline simplify smallmolecule supply network new operating model expected enable company deliver strategic financial operational flexibility necessary invest highest priorities across company aggregate restructuring charges million million incurred respectively actions including accelerated depreciation impairment charges resulting early site exits litigation settlements include million bms 's share patentinfringement settlement related merck 's pd antibody keytruda million related intellectual property product liability settlements including million recognized subsequent company 's earnings release fourth quarter divestiture gains includes divestiture multiple mature global product lines oncology infectious therapy additional contingent consideration diabetes business certain otc brands investigational hiv medicines businesses royalties licensing income includes keytruda royalties upfront licensing fees biogen roche connection licensing certain investigational genetically defined disease compounds contingent consideration erbitux diabetes business divestitures including transfer certain royalty rights pertaining diabetes product sales million fee amending royalty rate million salesbased milestone also included transition service fees included fees resulting divestiture diabetes investigational hiv medicines businesses pension postretirement includes interest cost expected return plan assets amortization components net periodic benefit cost credit well net charges settlements curtailments special termination benefits million million million intangible asset impairment includes million outlicensed asset obtained acquisition zymogenetics inc meet primary endpoint phase ii clinical study debt redemption loss million resulted early redemption certain longterm debt obligations income taxes dollars millions earnings income taxes provision income taxes effective tax rate impact specified items changes effective tax rate primarily due new us tax reform legislation known tax cuts jobs act act enacted december act moved worldwide tax system quasiterritorial tax system comprised broad complex changes us tax code including limited reduced us tax rate added deemed repatriation transition tax certain foreign earnings profits generally eliminated us federal income taxes dividends foreign subsidiaries included certain income controlled foreign companies us taxable income gilti created new minimum tax referred base erosion antiabuse income tax limited certain researchbased credits eliminated domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment act additional expense increased effective tax rate included billion onetime deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining million additional tax expense included adjustment measure net deferred tax assets new us tax rate accounting reduction deferred tax assets tax rate complete december provisional tax charge deemed repatriation transition tax reduced million upon completion accounting reduced effective tax rate addition tax impact attributed specified items including nondeductible rd charges valuation allowances certain tax assets resulting equity investment losses jurisdiction tax rates increased effective tax rate considering impact specified items including transitional impacts act discussed effective tax rate decreased primarily due ongoing impact act tax reserve releases partially offset taxes attributed internal cash repatriations earnings mix high low tax jurisdictions considering impact specified items effective tax rate decreased primarily due adoption amended income tax accounting guidance related sharebased payments early adoption intraentity transfers assets inventory partially offset earnings mix high low tax jurisdictions refer item financial statements supplementary datanote income taxes information nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative future operating results similar charges gains recognized prior periods likely reoccur future periods including restructuring costs accelerated depreciation impairment property plant equipment intangible assets rd charges connection acquisition licensing third party intellectual property rights divestiture gains losses pension legal contractual settlement charges debt redemption gains losses among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates nongaap information intended portray results baseline performance supplement enhance management analysts investors ' overall understanding underlying financial performance facilitate comparisons among current past future periods example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions impairment charges accelerated depreciation shutdown costs cost products sold marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development lossgain equity investmentsa provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement intangible asset impairment loss debt redemption income net increase pretax income income taxes items income taxes attributed us tax reform income taxes increase net earnings noncontrolling interest increase net earnings used diluted nongaap eps calculation specified items included amounts upon adoption amended guidance recognition measurement financial assets liabilities reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm debt obligations longterm debt net cash position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily international affiliates local operating needs subject onetime deemed repatriation transition tax billion payable next eight years result us tax reform expect flexibility accessing cash future cash may generated foreign subsidiaries believe existing cash cash equivalents marketable securities together cash generated operations issuance commercial paper us sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital deemed repatriation transition tax billion debt maturing management continuously evaluates companys capital structure ensure company financed efficiently may result repurchase common stock debt securities termination interest rate swap contracts prior maturity issuance debt securities average amount commercial paper outstanding million weightedaverage rate maximum amount commercial paper outstanding million outstanding borrowings december dividend payments billion billion dividend decisions made quarterly basis board directors annual capital expenditures approximately billion billion billion expected approximately million million continue expand biologics manufacturing capabilities facilityrelated activities example constructed new large scale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio approved commercial use early also paid billion nektar certain collaboration rights million shares common stock representing ownership interest investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors investment policy establishes limits amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statements supplementary datanote financial instruments fair value measurements information december three revolving credit facilities totaling billion consisted day billion facility scheduled expire march two fiveyear billion facilities extended september july respectively facilities provide customary terms conditions financial covenants two billion revolving facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving facilities december connection pending acquisition celgene january entered bridge commitment letter provides billion day senior unsecured bridge loan facility also entered billion term loan credit agreement consisting billion day tranche billion threeyear tranche billion fiveyear tranche term loan reduced commitments bridge facility billion obtain additional funding issuing securities obtaining loans amount bridge facility correspondingly reduced bridge loan term loan subject customary terms conditions financial covenants amounts borrowed either bridge loan term loan prior closing pending acquisition celgene january also entered two new revolving credit facilities totaling billion day billion facility expiring january threeyear billion facility expiring january day billion facility replaced existing day billion revolving facility terminated concurrently upon effectiveness new day facility supports commercial paper borrowings facilities provide customary terms conditions financial covenants borrowings outstanding two revolving facilities two billion revolving facilities february following announcement pending acquisition celgene also entered forward starting interest rate swap option contracts swaptions total notional value billion hedge future interest rate risk associated anticipated issuance longterm debt fund acquisition swaptions provide us right enter forward starting interest rate swap contracts periods years january additional regulations us could passed future including additional healthcare reform initiatives changes tax laws additional pricing laws potential importation restrictions may reduce results operations operating cash flow liquidity financial flexibility continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers believe economic conditions material impact liquidity cash flow financial flexibility uk voted depart eu june similar companies industry certain regulatory trade labor aspects business likely affected time however currently believe matters related financial effects material impact consolidated results operations financial position liquidity sales uk represent less consolidated revenues credit ratings january moody 's placed bms review downgrade standard poor 's placed bms creditwatch negative implications following announcement acquire celgene bms 's current longterm shortterm credit ratings assigned moody 's investors service prime respectively bms 's current longterm shortterm credit ratings assigned standard poor 's respectively longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally current longterm short term ratings reflect impact proposed acquisition celgene cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business example annual employee bonuses typically paid first quarter subsequent year addition cash collections continue impacted longer payment terms certain biologic products us primarily newer oncology products including opdivo yervoy empliciti days days longer payment terms used closely align insurance reimbursement timing physicians cancer centers following administration patients million change cash flow operating activities compared primarily attributable higher cash collections timing payments ordinary course business approximately billion partially offset higher rd licensing collaboration payments approximately million primarily due nektar transaction lower litigation settlement proceeds approximately million primarily due merck settlement lower outlicense proceeds approximately million primarily due biogen roche transactions billion change cash flow operating activities compared primarily attributable higher cash collections timing payments ordinary course business approximately million lower income tax payments approximately billion litigation settlement proceeds approximately million primarily due merck settlement outlicensing proceeds million primarily due biogen roche transactions partially offset higher rd licensing payments approximately million primarily due cytomx halozyme nitto denko transactions higher contributions pension plans approximately million investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities original maturities greater days time purchase reduced proceeds business divestitures including royalties sale maturity marketable securities million change cash flow investing activities compared primarily attributable lower net sales maturities marketable securities maturities greater days approximately million higher net acquisition payments approximately million primarily due purchase million shares nektar common stock partially offset higher business divestiture proceeds approximately million primarily due divestiture manufacturing operations swords ireland certain mature brands billion change cash flow investing activities compared primarily attributable lower net sales marketable securities maturities greater days approximately million lower business divestiture proceeds approximately million primarily due certain otc brands investigational hiv medicines businesses higher asset acquisition payments approximately million primarily due acquisition ifm financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings million change cash flow financing activities compared primarily attributable lower repurchases common stock billion primarily due accelerated share repurchase agreements partially offset lower net borrowings billion primarily due issuance longterm debt used repurchase common stock billion change cash flow financing activities compared primarily attributable higher repurchase common stock billion primarily due accelerated share repurchase agreements partially offset higher net borrowing activity million primarily fund repurchase common stock contractual obligations offbalance sheet arrangements payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb deemed repatriation transition tax total c includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution c excludes pension liabilities uncertainties regarding timing resolution addition committed aggregated billion potential future research development milestone payments third parties licensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical studies latestage milestones billion milestones achieved post phase iii clinical studies payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statements supplementary datanote alliances information regarding alliances offbalance sheet arrangements material reasonably likely become material financial condition results operations sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain dsas us pharmaceutical wholesalers account nearly gross us revenues current terms dsas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards recently issued accounting standards refer item financial statements supplementary datanote accounting policies recently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized following five step model identify customer contract identify contract 's performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue also reduced gtn sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revise information actual experience gtn adjustments following categories gtn adjustments involve significant estimates judgments information obtained external sources refer item financial statements supplementary datanote revenue discussion analysis significant category gtn sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount cms medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability rebates returns discounts adjustments gtn sales adjustments include sales returns programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loe estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model estimated levels inventory distribution channel projected demand estimated amount product returns presented liability use information external sources information external sources used estimate gtn adjustments estimate inventory wholesalers based projected prescription demand based sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information pension benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover lump sum election rates healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citi pension discount curve used us plans present value benefit obligations december us pension plans determined using discount rate assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately million expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments bristolmyers squibb retirement income plan 's pension expense determined using average expected longterm rate return plan assets us plans ' pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits refer item financial statements supplementary datanote retirement benefits longlived assets intangible assets intangible assets billion december including licenses million million allocated unapproved products developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loe pricing pressures adverse regulatory changes clinical study results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation property plant equipment property plant equipment tested impairment whenever current facts circumstances require review including whether likely asset disposed prior estimated remaining useful life additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use accelerated depreciation impairment related charges certain manufacturing rd facilities million million million additional charges continue occur result companys restructuring actions announced assets heldforsale following criteria considered concluding assets classified heldforsale managements commitment plan sell availability immediate sale present condition initiation active program identify buyer probability completed sale within one year actively marketed sale reasonable price relation current fair value likelihood significant changes plan made plan withdrawn criteria met balance sheet date assets liabilities presented separately balance sheet heldforsale lower carrying amount fair value less costs sell longer depreciated amortized classified heldforsale classified million assets million liabilities heldforsale december related planned sale upsa consumer health business division bms manufactures markets pain treatment otc products domestic sale france export sales outside france income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expired varying amounts beginning certain amounts unlimited lives discussed fully item financial statements supplementary datanote income taxes provisional tax charge billion attributable onetime deemed repatriation transition tax certain foreign earnings recognized fourth quarter accounting reduction deferred tax assets tax rate complete december tax charge deemed repatriation transition tax complete december provisional tax charge deemed repatriation transition tax reduced million prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes refer item financial statements supplementary datanote accounting policies recently issued accounting standardsincome taxes note income taxes contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statements supplementary datanote accounting policies recently issued accounting standardscontingencies note income taxes note legal proceedings contingencies product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance earlystage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represent approximately annual rd expenses last three years opdivo investigational compound marketed product represented greater rd expenses last three years latestage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following developments marketed products latestage pipeline product indication date developments august approval japan treatment adjuvant melanoma ec approval adjuvant treatment adult patients involvement lymph nodes metastatic disease july undergone complete resection melanoma announced results phase iii checkmate trial evaluating opdivo versus yervoy patients stage iiibc stage iv melanoma high risk recurrence following complete surgical resection june demonstrated statistically longer recurrencefree survival opdivo primary endpoint study versus yervoy minimum followup months across key subgroups including disease stages braf mutation status announced june fda lifted partial clinical hold placed checkmate randomized openlabel phase iii study evaluating addition opdivo pomalidomide dexamethasone patients multiple myeloma juneaugust relapsed refractory multiple myeloma decision follows consultation fda agreement amendments study protocol august company discontinued enrollment study following futility analysis approval china treatment locally advanced metastatic nsclc prior platinumbased june chemotherapy adult patients without egfr alk genomic tumor aberrations nsclc announced pivotal randomized phase iii checkmate trial evaluating opdivo versus docetaxel april predominantly chinese population previously treated advanced nsclc demonstrated superior overall survival benefit primary endpoint regardless pdl expression tumor histology acceptance china sbla filing patients previously treated metastatic recurrent january scchn scchn announced twoyear overall survival data checkmate phase iii study evaluating opdivo compared opdivo april investigators choice chemotherapy cetuximab docetaxel methotrexate patients recurrent metastatic scchn failure platinumbased therapy announced topline results phase iii checkmate study meet primary endpoint october overall survival opdivo versus chemotherapy patients previously treated relapsed sclc sclc fda approval first io treatment option patients metastatic sclc whose cancer august progressed platinumbased chemotherapy least one line therapy august approval japan patients mpm progressed chemotherapy approval japan every week minute infusion dose administration schedule opdivo six august indications announced preliminary data ongoing pivot phase iii study evaluating combination opdivo nektar 's investigational medicine nktr preliminary results presented june american society clinical oncology reported safety efficacy biomarker data patients enrolled phase doseescalation stage study first patients consecutively enrolled select dose various expansion cohorts phase ii ec approval every fourweek qw opdivo dosing schedule mg infused minutes option patients advanced melanoma previously treated rcc well approval twoweek april opdivo dosing option mg infused minutes replace weightbased dosing six approved monotherapy indications eu fda approval company 's sbla update opdivo dosing include mg infused every four weeks march majority approved indications well shorter minute infusion across approved indications product indication date developments announced new data cohort checkmate study opdivo plus lowdose october yervoy demonstrated durable clinical benefit firstline treatment patients msih dmmr mcrc crc fda approval opdivo plus lowdose yervoy treatment adult pediatric patients years july older msih dmmr mcrc progressed following treatment fluoropyrimidine oxaliplatin irinotecan announced results interim analysis phase ii checkmate trial evaluating opdivoyervoy patients mcrpc showed among asymptomatic minimally symptomatic patients whose disease progressed secondgeneration hormone therapy received chemotherapy cohort mcrpc february median followup months objective response rate additionally among patients whose disease progressed taxanebased chemotherapy cohort median followup months objective response rate announced fouryear data phase iii checkmate clinical trial continues demonstrate october durable longterm survival benefits firstline combination opdivoyervoy versus yervoy alone melanoma patients advanced melanoma approval japan opdivoyervoy combination chemotherapynaive patients unresectable may melanoma announced followup data evaluating opdivo monotherapy opdivo combination yervoy patients platinumpretreated muc results phase iii checkmate trial showed patients muc october received combination opdivo mgkg plus yervoy mgkg experienced higher objective response rate compared received opdivo mgkg plus yervoy mgkg opdivo alone announced voluntary withdrawal company 's sbla opdivo plus lowdose yervoy treatment january firstline advanced nsclc patients tmb greater equal mutations per megabase data checkmate part available within pdufa goal date may opdivoyervoy announced updates regarding regulatory actions chmp eu ongoing review applications indication metastatic firstline nsclc opdivo plus lowdose yervoy patients october tmb greater equal mutations per megabase chmp requested additional information nsclc checkmate including overall survival analysis opdivoyervoy patients tmb less mutations per megabase announced results part phase iii checkmate trial evaluated opdivo plus lowdose june yervoy opdivo plus chemotherapy versus chemotherapy patients firstline nsclc pdl expression across squamous nonsquamous tumor histologies extended progressionfree survival announced ema validated type ii variation application treatment adult patients firstline may metastatic nsclc tmb greater equal mutations per megabase announced new results phase iii checkmate study showing therapy opdivo plus low february dose yervoy continued demonstrate longterm survival benefits patients previously untreated advanced metastatic rcc announced ec approval opdivo plus lowdose yervoy previously untreated patients january intermediate poorrisk advanced rcc rcc august approval japan opdivo plus lowdose yervoy treatment unresectable metastatic rcc announced patientreported outcomes data phase iii checkmate trial intermediate poor june risk patients advanced rcc treated opdivo plus lowdose yervoy versus sunitinib twoyear followup period reported significant sustained healthrelated quality life improvements fda approval opdivoyervoy combination previously untreated patients intermediate poor april risk advanced rcc announced patientreported outcomes phase iii checkmate study meet primary sclc november endpoint overall survival opdivoyervoy versus placebo maintenance therapy patients extensivestage sclc completion firstline platinumbased chemotherapy announced findings largest realworld data analysis nvaf patient populations aged older eliquis nvaf november receiving direct oral anticoagulants showing eliquis associated lower rates stroke systemic embolism major bleeding rivaroxaban dabigatran product indication date developments received positive chmp opinion polyarticular jia via subcutaneous injection pediatric patients orencia jia january two years age fda approval empliciti injection intravenous use combination pomalidomide dexamethasone november treatment adult patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor empliciti rrmm announced ema validated company 's type ii variation application empliciti combination pomalidomide lowdose dexamethasone treatment adult patients multiple myeloma september received least two prior therapies including lenalidomide proteasome inhibitor pi demonstrated disease progression last therapy announced ec approval sprycel tablet powder oral suspension formulations combination february chemotherapy treatment pediatric patients newly diagnosed philadelphia chromosome positive sprycel fda expanded indication sprycel include treatment pediatric patients one year age older december newly diagnosed philadelphia chromosomepositive combination chemotherapy ec expanded indication sprycel include treatment children adolescents aged year cml july years chronic phase philadelphia chromosome positive cml include powder oral suspension yervoy melanoma january ec approval advanced unresectable metastatic melanoma pediatric patients years age older announced results phase ii study bms oral selective tyk inhibitor delivered tyk inhibitor psoriasis september significant skin clearance patients moderate severe plaque psoriasis special note regarding forwardlooking statements including documents incorporated reference written oral statements make time time contain certain forward looking statements within meaning section securities act amended section e exchange act identify forwardlooking statements fact use words could expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based historical performance current expectations projections future financial results goals plans objectives involve inherent risks assumptions uncertainties including internal external factors could delay divert change next several years could cause future financial results goals plans objectives differ materially expressed implied statements statements likely relate among things goals plans objectives regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products pending acquisition celgene outcome contingencies legal proceedings financial results forwardlooking statement guaranteed included important factors cautionary statements included particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made additional risks may currently deem immaterial presently known us could also cause forwardlooking events discussed occur except otherwise required federal securities law undertake obligation release publicly updates revisions forwardlooking statements result new information future events changed circumstances otherwise date item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen foreign currency forward contracts used manage risk primarily arising certain intercompany purchases sales transactions also exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million million december december respectively reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive loss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer item financial statements supplementary datanote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges provide appropriate balance fixed floating rate debt use cross currency interest rate swap contracts designated hedge company 's net investment japan subsidiary fair values contracts well marketable debt securities analyzed yearend determine sensitivity interest rate changes sensitivity analysis basis point increase shortterm longterm interest rates december december expected adverse impact earnings would material estimate increase basis points longterm interest rates december december would decrease fair value longterm debt million million respectively credit risk monitor investments counterparties objective minimizing concentrations credit risk investment policy invest institutions meet high credit quality standards establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statements supplementary datanote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative research development income net total expenses earnings income taxes provision income taxes net earnings noncontrolling interest net earnings attributable bms earnings per common share basic diluted consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive lossincome net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive lossincome comprehensive income comprehensive incomeloss attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm debt obligations accounts payable accrued liabilities deferred income income taxes payable total current liabilities deferred income income taxes payable pension liabilities longterm debt total liabilities commitments contingencies equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million common shares total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization divestiture gains royalties asset acquisition charges lossgain equity investments adjustments changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable securities purchase marketable securities capital expenditures divestiture proceeds acquisition payments net cash used inprovided investing activities cash flows financing activities shortterm debt obligations net issuance longterm debt repayment longterm debt repurchase common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions determination single segment consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information product regional revenue see note revenue use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation lossgain equity investments previously presented impairment charges adjustments consolidated statements cash flows presented separately revenue recognition effective january adopted asc using modified retrospective method refer note revenue detailed discussion accounting policies related revenue recognition including deferred revenue royalties refer note alliances detail regarding alliances income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable debt securities marketable debt securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity marketable debt securities reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition investments equity securities investments equity securities readily determinable fair values recorded fair value changes fair value recorded income net investments equity securities without readily determinable fair values recorded cost minus impairment plus minus changes estimated fair value resulting observable price changes orderly transactions identical similar investment issuer changes estimated fair value investments equity securities without readily determinable fair values recorded income net investments less owned companies accounted using equity method accounting ability exercise significant influence operating financial decisions investee maintained share net income losses equity investments accounted using equity method included income net investments equity securities without readily determinable fair values investments equity accounted using equity method assessed potential impairment quarterly basis based qualitative factors inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions amounts allocated lead investigational compounds asset acquisitions expensed date acquisition goodwill acquired inprocess research development intangible assets fair value acquired intangible assets typically determined using incomebased approach referred excess earnings method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value impairment charges recognized extent carrying value iprd determined exceed fair value finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations reduce number facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred advertising product promotion costs advertising product promotion costs expensed incurred advertising product promotion costs included marketing selling administrative expenses million million million foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive lossincome research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred research development costs presented net reimbursements alliance partners upfront contingent development milestone payments asset acquisitions investigational compounds also included research development expense alternative future uses cash flow payments licensing asset acquisitions investigational compounds included operating activities well outlicensing proceeds payments acquisition ownership interest legal entity including acquisitions meet accounting definition business included investing activities well divestiture proceeds royalties consideration received subsequent related sale asset business adjustments reflected operating activities include divestiture gains losses related royalties asset acquisition charges gains losses equity investments gains losses debt redemption recently adopted accounting standards revenue contracts customers amended guidance revenue recognition adopted first quarter using modified retrospective method cumulative effect change recognized retained earnings new guidance referred asc requires entity recognize amount revenue expects entitled transfer promised goods services customers replaces existing revenue recognition standards us gaap fivestep model utilized achieve core principle identify customer contract identify contracts performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied timing recognizing revenue typical net product sales customers significantly change however transaction prices longer required fixed determinable certain variable consideration might recognized prior occurrence resolution contingent event result certain revenue previously deferred prior standard transaction price fixed determinable accounted variable consideration might recognized earlier provided terms sufficient reliably estimate ultimate price expected realized estimated future royalties contingent fees related certain arrangements recognized prior third party sale event occurring extent probable significant reversal amount estimated cumulative revenue occur new guidance pertaining separation licensing rights related fee recognition significantly change timing recognizing revenue existing alliance arrangements currently generating revenue timing royalties salesbased milestones forms contingent consideration resulting divestiture businesses well royalties salesbased milestones licensing arrangements change cumulative effect accounting change resulted recognizing contract assets million million increase retained earnings net tax cumulative effect primarily attributed royalties licensing rights reacquired alliance partners expected received future eligible licensing exclusion result new guidance cumulative effect adjustment revenue approximately million lower compared would reported previous guidance refer note revenue information gains losses derecognition nonfinancial assets amended guidance gains losses derecognition nonfinancial assets asc adopted first quarter using modified retrospective method amendments clarify scope asset derecognition guidance add guidance partial sales nonfinancial assets clarify recognizing gains losses transfer nonfinancial assets contracts noncustomers certain transactions sale transfer product rights constitute business require accounting similar asc including potential recognition variable consideration amended guidance may result earlier recognition variable consideration depending facts circumstances transaction cumulative effect accounting change resulted recognizing contract assets million million increase retained earnings net tax cumulative effect primarily attributed royalties termination fees licensing rights reacquired third parties expected received future eligible licensing exclusion result new guidance cumulative effect adjustment income net approximately million lower compared would reported previous guidance presentation net periodic pension postretirement benefits amended guidance requiring net periodic benefit components defined benefit pension postretirement plans service costs recorded outside income operations income adopted first quarter retrospective basis cost products sold marketing selling administrative research development expenses increased aggregate corresponding offset income net adjusted amounts upon adoption new guidance follows year ended december dollars millions reported adjusted reported adjusted cost products sold marketing selling administrative research development income net definition business amended guidance revises definition business adopted prospectively first quarter amendments provide initial screen substantially fair value gross assets acquired disposed concentrated single identifiable asset group similar identifiable assets integrated set assets activities would represent business screen met set must include input substantive process together significantly contribute ability create outputs set represent business amendment also narrows definition term output requires transfer organized work force outputs exist amended guidance may result transactions accounted assets future impact results operations dependent individual facts circumstances transaction recognition measurement financial assets liabilities amended guidance recognition measurement presentation disclosures financial instruments adopted using modified retrospective method first quarter new guidance requires fair value adjustments equity investments readily determinable fair values reported earnings new guidance also requires qualitative impairment assessment equity investments without readily determinable fair value based upon observable price changes charge earnings impairment exists cumulative effect accounting change resulted million reduction comprehensive lossincome corresponding million increase retained earnings net tax refer note income net information impact results operations accounting hedging activities amended guidance derivatives hedging adopted using modified retrospective method first quarter amended guidance revises expands items eligible hedge accounting simplifies hedge effectiveness testing changes timing recognition presentation certain hedged items certain disclosure requirements also modified hedging activities prospective basis adoption amended standard material impact companys results operations reclassification certain tax effects accumulated comprehensive income amended guidance reclassification certain tax effects accumulated comprehensive income adopted prospectively fourth quarter new guidance permits reclassification income tax effect amounts recorded within accumulated comprehensive income impacted tax cuts jobs act retained earnings company recorded cumulative effect adjustment increase accumulated comprehensive loss million corresponding increase retained earnings collaborative arrangements amended guidance clarifying interaction asc revenue contracts customers asc collaborative arrangements adopted retrospectively first quarter amended guidance clarifies certain transactions collaborative arrangement participants accounted presented revenue asc adoption amended guidance impact companys results operations recently issued accounting standards yet adopted leases february fasb issued amended guidance lease accounting amended guidance requires recognition rightofuse asset lease liability initially measured present value future lease payments leases term longer months amended guidance adopted january modified retrospective approach company 's assessment amended guidance substantially complete including implementation leasing software system procured third party vendor gathering lease information data assessment reasonable certainty exercising renewal termination options evaluation changes enhancements processes internal controls based assessment intend elect package practical expedients adoption apply shortterm lease recognition exemption leases terms months less include option purchase underlying asset reasonably certain exercise apply portfolio approach discount real property lease liabilities using company 's incremental borrowing rate real property leases provide implicit rate lease terms vary based nature operations market dynamics country however leased facilities classified operating leases remaining lease terms years comprise approximately total lease obligation discounted value approximately million december amended guidance expected materially impact companys results operations recognition rightofuse asset lease liability sublease income material company 's results operations cumulative effect accounting change expected material company 's results operations financial instruments measurement credit losses june fasb issued amended guidance measurement credit losses financial instruments entities required use forwardlooking estimated loss model availableforsale debt security credit losses recognized allowances rather reduction amortized cost guidance effective january early adoption permitted modified retrospective approach amended guidance expected materially impact companys results operations goodwill impairment testing january fasb issued amended guidance simplifies recognition measurement goodwill impairment loss eliminating step quantitative impairment test result impairment charges required amount reporting units carrying amount exceeds fair value amount allocated goodwill guidance effective prospective basis january early adoption permitted interim annual goodwill impairment tests performed january amended guidance expected materially impact companys results operations note revenue following table summarizes disaggregation revenue nature year ended december dollars millions net product sales alliance revenues revenues total revenues net product sales represent companys total revenues years ended december products sold principally wholesalers distributors lesser extent directly retailers hospitals clinics government agencies pharmacies customer orders generally fulfilled within days receipt resulting minimal order backlog contractual performance obligations usually limited transfer control product customer transfer occurs either upon shipment upon receipt product certain nonus countries considering customer obtains legal title product company obtains right payment points customers able direct use obtain substantially remaining benefits product gross revenue three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc wholesalers initially invoiced contractual list prices payment terms typically days based customary practices country exception certain biologic products us including opdivo yervoy empliciti days days revenue reduced wholesaler list price time recognition expected chargebacks discounts rebates sales allowances product returns referred gtn adjustments reductions attributed various commercial arrangements managed healthcare organizations government programs medicare medicaid b drug pricing program containing various pricing implications mandatory discounts pricing protection wholesaler list price discounts medicare part beneficiaries coverage gap addition nonus government programs include different pricing schemes cost caps volume discounts outcome based pricing pricing clawbacks determined sales individual companies aggregation companies participating specific market chargebacks cash discounts reflected reduction receivables settled issuance credits customer typically within one month rebates discounts adjustments including medicaid medicare reflected liability settled cash payments customer typically within various time periods ranging months one year significant judgment required estimating gtn adjustments considering legal interpretations applicable laws regulations historical experience payer channel mix current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel following table summarizes gtn adjustments year ended december dollars millions gross product sales gtn adjustmentsa chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales includes adjustments provisions product sales made prior periods resulting changes estimates million million million years ended december respectively alliance revenues consist primarily amounts related collaborations outlicensing arrangements arrangements evaluated whether represent contracts within scope revenue recognition guidance entirety contain aspects within scope guidance either directly reference based upon application guidance related derecognition nonfinancial assets asc performance obligations identified separated party benefit directly rights goods services either together readily available resources rights goods services highly interdependent interrelated transaction prices arrangements may include fixed upfront amounts well variable consideration contingent development regulatory milestones salesbased milestones royalties likely amount method used estimate contingent development regulatory salesbased milestones ultimate outcomes binary nature expected value method used estimate royalties broad range potential outcomes exist except instances royalties relate license variable consideration included transaction price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved significant judgment required estimating amount variable consideration recognize assessing factors outside bmss influence likelihood regulatory success limited availability third party information expected duration time resolution lack relevant past experience historical practice offering fee concessions large number broad range possible amounts extent arrangements include multiple performance obligations separable transaction price assigned distinct performance obligation reflective relative standalone selling price recognized point time upon transfer control three types outlicensing arrangements typically utilized arrangements outlicense intellectual property another party performance obligations arrangements include license additional performance obligation supply product upon request third party collaboration arrangements include transferring license third party jointly develop commercialize product outlicensing arrangements consist single performance obligation satisfied upon execution agreement development commercialization rights transferred third party upfront fees recognized immediately included income net although contingent development regulatory milestone amounts assessed period likelihood achievement typically constrained recognized uncertainty subsequently resolved full amount milestone included income net salesbased milestones royalties recognized milestone achieved subsequent sales occur salesbased milestones included income net royalties included alliance revenue certain outlicensing arrangements may also include contingent performance obligations supply commercial product third party upon request license supply obligations accounted separate performance obligations considered distinct third party benefit license either together supply resources readily available obligations separately identifiable obligations contract accordance revenue recognition guidance considering standalone selling prices situations upfront fees contingent development regulatory milestone amounts salesbased milestone royalties allocated license recognized manner described consideration supply obligation usually based upon stipulated costplus margin contractual terms represent standalone selling price supply consideration recognized point time upon transfer control product third party included alliance revenue fee allocation license supply represents amount consideration company expects entitled satisfaction separate performance obligations although collaboration arrangements unique nature parties active participants operating activities exposed significant risks rewards depending commercial success activities performance obligations inherent arrangements may include transfer certain development commercialization rights ongoing development commercialization services product supply obligations except certain product supply obligations considered distinct accounted separate performance obligations similar manner discussed performance obligations considered distinct combined single performance obligation since transferred rights highly integrated interrelated obligation jointly develop commercialize product third party result upfront fees recognized ratably time throughout expected period collaboration activities included income net license combined development commercialization obligations contingent development regulatory milestones longer constrained recognized similar manner prospective basis royalties profit sharing recognized underlying sales profits occur included alliance revenue refer note alliances information following table summarizes disaggregation revenue product region year ended december dollars millions prioritized brands opdivo eliquis orencia sprycel yervoy empliciti established brands baraclude reyataz franchise sustiva franchise hepatitis c franchise brands total revenues united states europe rest world othera total revenues revenues included royalties alliancerelated revenues products sold regional commercial organizations following table summarizes contract assets december january dollars millions december january prepaid expenses assets total contract assets contract assets primarily estimated future royalties termination fees eligible licensing exclusion therefore recognized upon adoption asc asc contract assets reduced receivables increased period underlying sales occur contingent development regulatory milestones outlicensing arrangements billion constrained recognized considering likelihood significant reversal cumulative amount revenue occurring cumulative catchup adjustments revenue affecting contract assets contract liabilities material year ended december revenue recognized performance obligation satisfied prior periods million year ended december consisting primarily royalties outlicensing arrangements revised estimates gtn adjustments related prior period sales sales commissions incremental costs obtaining customer contracts expensed incurred amortization periods would less one year note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions refer collaborations alliances partners alliance partners common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenues sale commercial products considered part bms 's ongoing major central operations refer note revenue information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenues sale commercial products considered part bms 's ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized expected period bms 's development copromotion obligation market exclusivity period periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented income net activities performed time related sale commercial products included bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expense royalties contingent consideration payable bms alliance partners related divestiture businesses included income net earned payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized certain prior period amounts included revised exclude amounts arrangements longer meet criteria collaboration arrangements year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development income net selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone payments specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms sales based fee coexclusive license rights granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms pfizer manufacture product alliance bms principal end customer product sales us significant countries europe well canada australia china japan south korea bms transferred full commercialization rights pfizer certain smaller countries order simplify operations transferred countries bms supplies product pfizer cost plus percentage net sales price endcustomers recorded full upon transfer control product pfizer company allocate consideration rights transferred pfizer rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized expected period bms 's co promotion obligation market exclusivity period bms received million nonrefundable upfront milestone licensing payments related eliquis december amortization eliquis deferred income included income net eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing income net amortization deferred income selected alliance balance sheet information december dollars millions receivables accounts payable deferred income otsuka bms otsuka copromote sprycel us eu parties actively participate various governance committees however bms control decision making bms responsible development manufacture product also principal end customer product sales fee paid otsuka based net sales levels oncology territory us japan eu equates million first billion annual net sales plus net sales excess billion summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales oncology territory payments otsuka cost products sold oncology fee bms also worldwide commercialization agreement otsuka codevelop copromote abilify us portion agreement expired april eu portion expired june countries bms exclusive right sell abilify expiration occurred countrybycountry basis last expiration canada january ono bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer ono granted bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights bms paid million ono included research development expense ono eligible receive subsequent clinical regulatory salesbased milestone payments million royalties countries bms exclusive licensing rights bms provided ono right accept nktr alliance upon completion phase clinical study opdivo nktr ono territory right exercised ono partially reimburse bms development costs incurred study share certain future development costs contingent milestone payments profits losses collaboration nektar summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues bms principal end customer product sales exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan ono entitled receive royalties north america territories excluding three countries listed subject customary adjustments gilead bms gilead operate joint venture europe develop commercialize combination product named atripla combines bms 's sustiva gilead 's truvada joint venture consolidated gilead principal end customer product sales bms receives percentage end customer sales recorded alliance revenues joint venture continue either party terminates arrangement last patent expires allows market exclusivity atripla prior bms gilead operated joint venture us canada atripla terminated following launch generic version sustiva thirdparty us result deferred income alliance receivables attributed sustiva product held joint venture december reduced million reflect posttermination selling price bms entitled fee equal atripla us net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price fee reduced atripla us net sales multiplied ratio described bms supplies sustiva cost plus markup gilead threeyear period may terminate supply agreement notice period summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates nektar bms nektar commenced worldwide license collaboration development commercialization nktr nektar 's investigational immunostimulatory therapy designed selectively expand specific cancerfighting cells natural killer cells directly tumor microenvironment opdivo nktr combination therapy currently phase ii clinical studies multiple cancer indications phase iii clinical studies melanoma rcc joint development plan agreed parties contemplates development various indications tumor types party responsible supply product bms 's share development costs associated therapies comprising bms medicine used combination nktr subject certain cost caps nektar parties also jointly commercialize therapies subject regulatory approval bms 's share global nktr profits losses subject certain annual loss caps nektar bms paid nektar billion rights discussed million shares nektar common stock representing ownership interest bms 's equity ownership subject certain lockup standstill voting provisions fiveyear period amount upfront payment allocated equity investment million considering nektar 's stock price date closing current limitations trading securities remaining billion front payment allocated rights discussed included research development expense second quarter bms also pay billion upon achievement contingent development regulatory salesbased milestones life alliance period research development expense payable agreement nektar million year ended december abbvie bms abbvie jointly develop commercialize empliciti humanized monoclonal antibody treatment multiple myeloma parties participate development us commercialization committees bms final decision making authority abbvie funds global development costs bms solely responsible supply distribution sales marketing activities principal end customer product sales abbvie shares profits losses us paid tiered royalties outside us abbvie also entitled receive additional million certain regulatory events occur million certain sales thresholds achieved agreement may terminated immediately bms either party material breaches subsequent notice period summarized financial information related alliance follows year ended december dollars millions revenues abbvie alliance net product sales payments abbvie cost products sold profit sharing note acquisitions divestitures licensing arrangements acquisitions acquisitions evaluated determine whether business asset group assets following transactions accounted asset acquisitions since determined business term defined asc primarily significant processes acquired result amounts allocated lead investigational compounds expensed capitalized consideration transaction upon execution last years allocated follows contingent dollars millions year upfront payment rd expense deferred tax assetsa consideration ifmb cormorant padlock relates net operating loss tax credit carryforwards b includes million certain negotiation rights collaborate license acquire nlrp antagonist program newly formed entity established former shareholders ifm ifm bms acquired outstanding shares ifm private biotechnology company focused developing therapies modulate novel targets innate immune system treat cancer autoimmunity inflammatory diseases acquisition provided bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer contingent consideration includes development regulatory salesbased milestone payments million included research development expense following commencement phase clinical study bms may pay million additional contingent milestones subsequent products selected ifm 's preclinical sting nlrp agonist programs included contingent consideration amount table cormorant bms acquired outstanding shares cormorant private pharmaceutical company focused developing therapies cancer rare diseases acquisition provided bms full rights cormorant 's lead candidate humaxil phase iii monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules contingent consideration includes development regulatory milestone payments million included research development expense upon conclusion month reversion option period padlock bms acquired outstanding shares padlock private biotechnology company dedicated creating new medicines treat destructive autoimmune diseases acquisition provided bms full rights padlocks pad inhibitor discovery program focused development potentially transformational treatment approaches patients ra padlocks pad discovery program may additional utility treating systemic lupus erythematosus autoimmune diseases contingent consideration includes development regulatory milestone payments cardioxyl bms acquired outstanding shares cardioxyl private biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure contingent consideration includes development regulatory salesbased milestone payments million included research development expense following commencement phase ii clinical study flexus bms acquired outstanding shares flexus private biotechnology company focused discovery development novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy addition bms acquired flexus 's idotdo discovery program includes idoselective idotdo dual tdoselective compounds contingent consideration includes development regulatory milestone payments million million included research development expense respectively following commencement phase phase ii phase iii clinical studies divestitures following table summarizes proceeds gains royalty income resulting divestitures revenue pretax earnings related divestitures assets heldforsale material periods presented excluding divestiture gains proceedsa divestiture gains royalty income dollars millions diabetes business erbitux business manufacturing operations plavix avaproavalide investigational hiv business otc business mature brands includes royalties received subsequent related sale asset business diabetes business february bms astrazeneca terminated diabetes business alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan purchase bmss manufacturing facility located mount vernon indiana consideration transaction included billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable tiered royalty payments ranging based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees consideration allocated development supply agreements amortized applicable service periods amortization deferred income attributed development agreement ended december million included income net sale services considered part bmss ongoing major central operations amortization deferred income attributed supply agreement ended december recorded alliance revenues revenues attributed supply agreement included alliance revenues material royalties presented income net million million million contingent consideration million received resulting additional gain upon achievement regulatory approval milestone september bms transferred percentage future royalty rights amylin net product sales us cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms received additional tieredbased royalty amylin net product sales us cppib royalties presented income net million million million november bms transferred percentage future royalty rights portion onglyza farxiga net product sales royalty pharma transferred rights represent approximately potential future royalties bms entitled products exchange transfer bms receive additional tieredbased royalty onglyza farxiga net product sales royalty pharma royalties presented income net million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly october bms transferred rights erbitux north america lilly exchange tiered salesbased royalties september included income net royalties earned million million million bms transferred cocommercialization rights japan merck kgaa exchange salesbased royalties included income net earned royalties earned million million result adoption asc first quarter estimated future royalties resulting transfer rights merck kgaa recorded cumulative effect adjustment retained earnings subsequent changes estimates recorded income net refer note accounting policies recently issued accounting standards details manufacturing operations bms sold small molecule active pharmaceutical ingredient manufacturing operations swords ireland sk biotek approximately million subject certain adjustments initial proceeds million received first quarter transaction accounted sale business divestiture includes transfer facility majority employees site inventories certain thirdparty contract manufacturing obligations assets reduced estimated relative fair value considering purchase price resulting impairment charge million included cost products sold sk biotek provide certain manufacturing services bms plavix avaproavalide sanofi reacquired bms 's codevelopment cocommercialization agreements plavix avaproavalide consideration transfer rights included quarterly royalties december million terminal payment received million allocated optout markets million allocated bms 's interest europe asia territory partnership royalties expected received portion terminal payment allocated optout markets reflected contract asset cumulative effect adjustment upon adoption asc bms fulfilled performance obligation million allocated bms 's partnership interest deferred december recognized income net transfer sanofi refer note accounting policies recently issued accounting standards details royalties earned sanofi territory covering americas australia optout markets presented alliance revenues aggregated million million million royalties attributed territory covering europe asia earned territory partnership paid bms included equity net income affiliates amounted million million million investigational hiv business bms sold investigational hiv medicines business consisting number rd programs different stages discovery development viiv healthcare bms received million also entitled receive viiv healthcare contingent development regulatory milestone payments billion salesbased milestone payments billion future tiered royalties bms earned transitional fees million million certain rd services respectively otc business bms sold reckitt otc business containing brands sold primarily mexico brazil million gain million including trademarks inventory certain assets exclusively related products manufacturing facility located mexico primarily dedicated products mature brands divestitures include several brands sold cheplapharm resulting proceeds million divestiture gains million assets heldforsale bms agreed sell upsa consumer health business billion transaction expected close second quarter accounted sale business business accounted heldforsale december accordingly assets million reclassified assets heldforsale included within prepaid expenses including million receivables million inventory million property plant equipment million goodwill additionally liabilities million reclassified liabilities related assets heldforsale included within accrued liabilities including million accrued liabilities million accounts payable million deferred tax liabilities million liabilities december bms agreed sell rd facility wallingford connecticut transaction closed accounted sale asset facility accounted heldforsale december reduced estimated relative fair value resulting impairment charge million included research development expense licensing arrangements promedior bms purchased warrant gives bms exclusive right acquire promedior biotechnology company whose lead asset prm developed treatment ipf mf warrant exercisable upon delivery phase ii data following either ipf mf phase ii clinical studies directed promedior upfront payment allocated warrant million included research development expense remaining million million upfront payment allocated promediors obligation complete phase ii studies amortized expected period phase ii studies allocation determined using level inputs bms notified promedior would exercise warrant purchase outstanding shares promedior halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology technology may allow rapid delivery large volume injectable medications subcutaneous delivery bms paid million halozyme access technology included research development expense bms designated multiple io targets including pd develop using enhanze technology option select additional targets within five years effective date maximum targets bms may pay contingent development regulatory salesbased milestones million achieved nominated collaboration targets additional milestone payments combination products future royalties sales products using enhanze technology cytomx bms expanded strategic collaboration cytomx discover novel therapies using cytomxs proprietary probody platform part original may collaboration discover develop commercialize probody therapeutics bms selected four oncology targets including ctla pursuant expanded agreement cytomx granted bms exclusive worldwide rights develop commercialize probody therapeutics eight additional targets bms paid cytomx million rights initial four targets expensed rd prior bms paid million cytomx access additional targets included research development expense bms also reimburse cytomx certain research costs collaboration period pay contingent development regulatory salesbased milestones million achieved collaboration target future royalties biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy biogen paid million bms included income net bms also entitled contingent development regulatory salesbased milestone payments million achieved future royalties bms originally acquired rights compound acquisition ipierian biogen assumed bmss remaining obligations former stockholders ipierian roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche paid million bms included income net bms also entitled contingent development regulatory milestone payments million achieved future royalties nitto denko bms nitto denko entered exclusive worldwide license agreement granting bms right develop commercialize nitto denko 's investigational sirna molecules targeting hsp vitamin containing formulations includes nitto denko 's lead asset ndls currently phase ii study treatment advanced liver fibrosis bms paid million nitto denko included research development expense bms may pay contingent development regulatory salesbased milestones million achieved future royalties agreement also grants bms option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung fibrosis organ fibrosis fstar bms acquired exclusive option purchase fstar lead asset fs antiher antibody fragment development treatment breast gastric cancer among welldefined population herpositive patients bms discontinued development fs exercise option resulting iprd charge million included research development expense attributed noncontrolling interest note income net year ended december dollars millions interest expense investment income lossgain equity investments provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investments includes fair value adjustment million related company 's equity investment nektar litigation settlements include million bms 's share patentinfringement settlement related merck 's pd antibody keytruda royalties licensing income includes royalties resulting business divestitures intellectual property legal settlements upfront licensing fees including million biogen roche transition service fees primarily related divestiture diabetes investigational hiv medicines businesses note restructuring october company announced restructuring plan evolve streamline operating model expects incur charges connection employee workforce reductions early site exits majority charges expected incurred range billion billion consist employee termination benefit costs contract termination costs accelerated depreciation impairment charges site exit costs cash outlays connection actions expected approximately total charges charges approximately billion recognized actions since announcement including impairment charge small molecule manufacturing operation swords ireland restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets restructuring charges addition actions recognized prior primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets addition accelerated depreciation charges incurred connection expected early exits small molecule manufacturing site cruiserath ireland rd facility wallingford connecticut refer note acquisitions divestitures licensing arrangements information employee workforce reductions approximately following tables summarize charges activity related restructuring actions year ended december dollars millions employee termination costs termination costs provision restructuring accelerated depreciation asset impairments shutdown costs total charges year ended december dollars millions cost products sold marketing selling administrative research development income net total charges year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation payments liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective tax rate us statutory federal income tax rate earnings income taxes dollars millions earnings income taxes us nonus total us statutory rate deemed repatriation transition tax deferred tax remeasurement global intangible low taxed income gilti foreign tax effect certain operations ireland puerto rico switzerland us federal valuation allowance us federal state foreign contingent tax matters us federal research based credits goodwill allocated divestitures us branded prescription drug fee nondeductible rd charges puerto rico excise tax domestic manufacturing deduction state local taxes net valuation allowance foreign new tax reform legislation enacted december known tax cuts jobs act act act moved worldwide tax system quasiterritorial tax system comprised broad complex changes us tax code including limited reduced us tax rate added deemed repatriation transition tax certain foreign earnings profits generally eliminated us federal income taxes dividends foreign subsidiaries included certain income controlled foreign companies us taxable income gilti created new minimum tax referred base erosion antiabuse income tax limited certain us federal research based credits eliminated domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment including billion onetime deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining additional tax expense included adjustment measure net deferred tax assets new us tax rate provisional tax charge deemed repatriation transition tax including related tax reserves staff accounting bulletin reduced million accounting reduction deferred tax assets tax rate complete december tax charge deemed repatriation transition tax complete december prior enactment act earnings certain manufacturing operations low tax jurisdictions switzerland ireland puerto rico indefinitely reinvested result transition tax act company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign state income withholding tax would apply company remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable bms operates favorable tax grant puerto rico scheduled expire prior valuation allowance set result nektar equity investment fair value losses would considered limited capital loss us federal state foreign contingent tax matters includes million tax benefit respect lapse statutes goodwill allocated business divestitures well us branded prescription drug fee deductible tax purposes rd charges primarily acquisition related milestone payments former shareholders deductible tax purposes include cormorant ifm flexus cardioxyl ifm flexus padlock cormorant puerto rico imposes excise tax gross company purchase price goods sold manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurs us income tax purposes excise tax deductible results foreign tax credits generally recognized provision income taxes excise tax incurred deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards deferred income milestone payments license fees pension postretirement benefits intercompany profit inventory items foreign deferred tax assets sharebased compensation total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities depreciation acquired intangible assets goodwill total deferred tax liabilities deferred tax assets net recognized deferred income taxes noncurrent income taxes payable noncurrent liabilities related assets heldforsale total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance billion established following items billion primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal deferred tax assets including equity fair value adjustments us federal net operating loss carryforwards changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions non us rate change balance end year income tax payments million million billion business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credit deductibility certain expenses deemed repatriation transition tax liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities proposed considering proposing material adjustments tax positions issues transfer pricing certain tax credits deductibility certain expenses reasonably possible new issues raised tax authorities may require adjustments amount unrecognized tax benefits however estimate adjustments reasonably made time also reasonably possible total amount unrecognized tax benefits december could decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits may result payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share basic earnings per share diluted note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective nav underlying investments level derivative instruments valued using libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available level financial assets liabilities december financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level cash cash equivalents money market securities marketable securities certificates deposit commercial paper corporate debt securities equity investments derivative assets equity investments derivative liabilities availableforsale securities changes fair value equity investments included income net upon adoption asu first quarter following table summarizes debt equity securities classified availableforsale december december gross unrealized gross unrealized amortized amortized dollars millions cost gains losses fair value cost gains losses fair value certificates deposit commercial paper corporate debt securities equity investmentsa equity investmentsb total december december dollars millions current marketable securities noncurrent marketable securitiesc assetsa total includes equity investments readily determinable fair values measured using fair value option december b includes equity fixed income funds measured using fair value option december refer note accounting policies recently issued accounting standards information c noncurrent marketable securities mature within five years december december equity investments measured fair value excluded table limited partnerships equity method investments million december million december equity investments without readily determinable fair values million december million december amounts included assets adjustments equity investments without readily determinable fair values million resulting observable price changes similar securities issuer recorded income net following table summarizes net loss recorded equity investments readily determinable fair values held december year ended december dollars millions net loss recognized less net gain recognized equity investments sold net unrealized loss equity investments held qualifying hedges nonqualifying derivatives cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchases sales transactions certain foreign currency transactions fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings upon adoption amended guidance derivatives hedging entire change fair value hedging instrument included assessment hedge effectiveness recorded derivatives qualifying cash flow hedges component comprehensive lossincome net gain loss foreign currency forward contracts expected reclassified net earnings primarily included cost products sold within next months notional amount outstanding foreign currency forward contracts primarily attributed euro billion japanese yen million december earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis foreign currency forward contracts designated hedging instruments used offset exposures certain foreign currency denominated assets liabilities earnings changes fair value derivatives recognized earnings occur net investment hedges nonus dollar borrowings million billion december designated hedge euro currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gain remeasurement euro debt million million respectively loss million recorded foreign currency translation component accumulated comprehensive loss related offset longterm debt january bms entered million crosscurrency interest rate swap contracts maturing december designated hedge japanese yen currency exposures company 's net investment japan subsidiary contract fair value changes recorded foreign currency translation component comprehensive lossincome related offset pension liabilities fair value hedges fixed floating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging gains losses resulting changes fair value underlying debt attributable hedged benchmark interest rate risk recorded interest expense associated offset carrying value debt since specific terms notional amount swap intended match debt hedged changes fair value swap recorded interest expense associated offset derivative asset liability consolidated balance sheet result net impact earnings underlying swap terminated prior maturity fair value adjustment underlying debt amortized reduction interest expense remaining term debt following summarizes fair value outstanding derivatives december december asseta liabilityb asseta liabilityb dollars millions notional fair value notional fair value notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts derivatives designated hedging instruments foreign currency forward contracts included prepaid expenses assets b included accrued liabilities pension liabilities following table summarizes financial statement classification amount gainloss recognized hedging instruments year ended december cost income cost income cost income dollars millions products sold net products sold net products sold net interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts following table summarizes effect derivative nonderivative instruments designated hedging instruments comprehensive lossincome year ended december dollars millions derivatives qualifying cash flow hedges foreign currency forward contracts gainloss recognized comprehensive lossincomea reclassified cost products sold reclassified income net derivatives qualifying net investment hedges crosscurrency interest rate swap contracts loss recognized comprehensive lossincome nonderivatives qualifying net investment hedges non us dollar borrowings gainloss recognized comprehensive lossincome amount expected reclassified earnings next months debt obligations shortterm debt obligations include december dollars millions commercial paper nonus shortterm borrowings current portion longterm debt total average amount commercial paper outstanding million million weightedaverage interest rate respectively maximum amount commercial paper outstanding million outstanding borrowings december maximum amount commercial paper outstanding billion million outstanding borrowings december longterm debt current portion longterm debt includes december dollars millions principal value notes due notes due notes due notes due notes due euro notes due notes due notes due euro notes due notes due notes due notes due notes due notes due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively valued using level inputs based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments senior unsecured notes issued registered public offerings notes rank equally right payment bms 's existing future senior unsecured indebtedness redeemable whole part time predetermined redemption price following table summarizes issuance long term debt obligations none dollars millions principal value notes due notes due total proceeds net discount deferred loan issuance costs forward starting interest rate swap contracts terminated notional amount realized gain unrealized loss bms repaid million notes maturity company repurchased certain longterm debt obligations interest rates ranging following summarizes debt redemption activity dollars millions principal amount carrying value debt redemption price loss debt redemptiona including acceleration debt issuance costs gain previously terminated interest rate swap contracts related fees interest payments million million million net amounts received interest rate swap contracts december company three separate revolving credit facilities totaling billion syndicate lenders including two billion facilities expiring september july extendable annually one year anniversary date consent lenders january existing day billion facility expiring march replaced new day billion facility expiring january new threeyear billion facility expiring january entered credit facilities provide customary terms conditions financial covenants borrowings outstanding revolving credit facility december available financial guarantees provided form bank overdraft facilities standby letters credit performance bonds approximately billion december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions note receivables december dollars millions trade receivables less chargebacks cash discounts less bad debt allowances net trade receivables alliance receivables prepaid refundable income taxes royalties vat receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization balance end year note inventories december dollars millions finished goods work process raw packaging materials inventories inventories assets assets include inventory expected remain hand beyond one year periods note property plant equipment leases december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment united states europe rest world total depreciation expense million million million annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expense approximately million million million sublease income capital lease obligations material periods presented note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years iprd gross intangible assets less accumulated amortization total intangible assets period adjustment included year ended december reduce goodwill increase accumulated comprehensive loss million attributed goodwill prior acquisitions foreign entities previously recorded correct local currency adjustment impact consolidated results operations material previously reported balance sheets amortization expense intangible assets million million million future annual amortization expense intangible assets expected approximately million million million million million intangible asset impairment charges million million million million impairment charge recorded income net outlicensed asset obtained acquisition zymogenetics inc meet primary endpoint phase ii clinical study million iprd charge recognized attributed noncontrolling interest bms declined exercise option purchase fstar note accrued liabilities december dollars millions rebates returns employee compensation benefits research development dividends royalties branded prescription drug fee liabilities related assets heldforsale litigation settlements restructuring pension postretirement benefits accrued liabilities note equity common stock capital treasury stock excess accumulated par value comprehensive retained noncontrolling dollars shares millions shares par value stock loss earnings shares cost interest balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation distributions balance december accounting change cumulative effecta adjusted balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation variable interest entity distributions balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation adoption asu b distributions balance december cumulative effect resulting adoption asu b refer note accounting policies recently issued accounting standards additional information c cash dividends declared per common share respectively bms stock repurchase program authorized board directors allowing repurchases open market private transactions including plans established accordance rule b securities exchange act stock repurchase program expiration date may suspended discontinued time treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method bms repurchased billion common stock accelerated share repurchase agreements agreements funded combination debt cash components comprehensive lossincome follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedges unrealized gainslosses reclassified net earningsa derivatives qualifying cash flow hedges pension postretirement benefits actuarial lossesgains amortizationb settlementsb pension postretirement benefits availableforsale securities unrealized lossesgains realized gainslossesb availableforsale securities foreign currency translation total comprehensive lossincome included cost products sold b included income net accumulated balances related component comprehensive lossincome net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note retirement benefits bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan plan covering us employees representing approximately consolidated pension plan assets obligations future benefits related service plan eliminated bms contributes least minimum amount required erisa plan benefits based primarily participants years credited service final average compensation december plan assets consist primarily fixedincome securities december bms announced plans fully terminate bristolmyers squibb retirement income plan plan pension obligations related plan billion distributed combination lump sum payments eligible plan participants elect payments purchase group annuity contract athene annuity life company athene whollyowned insurance subsidiary athene holding ltd benefit obligation plan december therefore determined plan termination basis assumed portion eligible active deferred vested participants elect lump sum payments remaining obligation expected transferred athene includes annuity purchase price premium plan sufficient assets satisfy transaction obligations transaction expected close third quarter time company expects record total noncash pretax pension settlement charge approximately billion billion net periodic benefit costcredit defined benefit pension plans includes dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss settlements curtailments special termination benefits net periodic benefit costcredit pension settlement charges recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements curtailments actuarial gainslosses benefits paid foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid foreign currency fair value plan assets end year funded status assetsliabilities recognized assets accrued liabilities pension liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans billion billion december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations december follows discount rate rate compensation increase weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit costcredit years ended december follows discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citi pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value approximated fair value plan assets december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets actuarial gains related plan benefit obligations primarily result increases discount rates actuarial losses related plan benefit obligations primarily result decreases discount rates gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan result adopting asu refer note accounting policies recently issued accounting standards details periodic benefit cost credit included income net except service cost component included cost products sold research development marketing selling administrative expenses postretirement benefit plans comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities postretirement benefit plan obligations million million december respectively fair value plan assets million million december respectively weightedaverage discount rate used determine benefit obligations december respectively net periodic benefit credits material plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities shortterm investment funds insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient equity funds venture capital limited partnerships total plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds shortterm investment funds classified level within fair value hierarchy valued nav shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company venture capital limited partnership investments typically redeemable distributions upon liquidation underlying assets significant unfunded commitments investments essentially liquidations expected occur end remaining investments using practical expedient redeemable weekly monthly basis investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses target allocation longduration fixed income private equity adopted maintained principal defined benefit pension plan bristolmyers squibb retirement income plan bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected material estimated annual future benefit payments nonterminating plans including lump sum payments approximately million next five years subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us approximately million note employee stock benefit plans may shareholders approved plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy obligations plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since restricted stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment number shares issued performance share units vest determined based achievement performance goals based company 's threeyear total shareholder return relative peer group companies vesting conditioned upon continuous employment occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows year ended december dollars millions restricted stock units market share units performance share units total stockbased compensation expense income tax benefit stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares millions outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value awards vested restricted stock units market share units performance share units total intrinsic value stock options exercised fair value restricted stock units market share units performance share units approximates closing trading price bms 's common stock grant date adjusting units eligible accrued dividends addition fair value market share units performance share units considers probability satisfying payout factor total shareholder return respectively following table summarizes significant outstanding exercisable options december number weightedaverage weightedaverage aggregate outstanding exercisable remaining contractual exercise price intrinsic value millions life years per share millions options outstanding exercisable aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex company apotex settled apotex case case dismissed australian government intervened matter seeking maximum damages million aud million plus interest would split company sanofi alleged losses experienced paying higher price branded plavix period injunction place company sanofi disputed australian government entitled damages australian government 's claim still pending trial concluded september company expecting decision sprycel europe may apotex actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions epo seeking revocation european patent patent covering dasatinib active ingredient sprycel january opposition division epo revoked patent may company appealed epos decision epo board appeal february epo board appeal upheld opposition divisions decision revoked patent orphan drug exclusivity data exclusivity sprycel eu expired november epo board appeals decision affect validity sprycel patents within outside europe including different patents cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reversed remanded invalidity decision european patent claim use dasatinib treat cml epos opposition division revoked october december epos opposition division upheld validity patent directed use dasatinib treat cml expires company intends take appropriate legal actions protect sprycel generics approved certain eu markets may experience decline european revenues event generic dasatinib product enters market antipd antibody patent oppositions litigation september danafarber cancer institute danafarber filed complaint massachusetts federal court seeking correct inventorship five related us patents directed methods treating cancer using pd pdl antibodies specifically danafarber seeking add two scientists inventors patents october pfizer allowed intervene case alleging one scientists identified danafarber employed company eventually acquired pfizer relevant period february company settled lawsuit pfizer bench trial lawsuit danafarber began february decision expected eliquis patent litigation us twentyfive generic companies sent company paragraphiv certification letters informing company filed andas seeking approval generic versions eliquis result two eliquis patents listed fda orange book challenged composition matter patent claiming apixaban specifically formulation patent april company along partner pfizer initiated patent lawsuits hatchwaxman act generic filers federal district courts delaware west virginia august us patent trademark office granted patent term restoration composition matter patent thereby restoring term eliquis composition matter patent companys basis projected loe february november company settled lawsuits number anda filers december settlements affect companys projected loe eliquis pricing sales promotional practices litigation plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix product liability litigation company party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits company also faces unfiled claims involving products byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf approximately active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer cases claiming alleged wrongful death majority cases pending federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendants ' motion summary judgment based federal preemption granted mdl jccp november ninth circuit reversed mdl summary judgment order remanded case mdl november california court appeal reversed state court dismissal state court cases remanded jccp proceedings amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca abilify company otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders cases filed state federal courts additional cases pending canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes us district court northern district florida february company otsuka entered master settlement agreement establishing proposed settlement program resolve abilify compulsivity claims filed january mdl well various state courts including california new jersey eliquis company pfizer codefendants product liability litigation related eliquis plaintiffs assert claims including claims wrongful death result bleeding allege caused use eliquis january claims remain pending mdl us district court southern district new york three cases remain pending state courts one remains pending canada cases dismissed prejudice mdl claims plaintiffs appeal second circuit court appeals company expects decision onglyza company astrazeneca codefendants product liability litigation related onglyza plaintiffs assert claims including claims wrongful death result heart failure cardiovascular injuries allege caused use onglyza january claims pending state federal court behalf approximately individuals allege ingested product suffered injury significant majority claims pending federal courts february judicial panel multidistrict litigation ordered federal cases transferred mdl us district court eastern district kentucky part companys global diabetes business divestiture company sold onglyza astrazeneca february potential liability respect onglyza expected shared astrazeneca shareholder derivative litigation since december three shareholder derivative lawsuits filed new york state court certain officers directors company plaintiffs allege among things breaches fiduciary duty surrounding companys previously disclosed october civil settlement sec alleged fcpa violations china company agreed payment approximately million disgorgement penalties interest october three lawsuits dismissed company received notice appeal one dismissed lawsuits oral argument appeal dismissal scheduled february securities litigation since february two separate putative class action complaints filed us district northern district california us district court southern district new york company companys chief executive officer giovanni caforio companys chief financial officer charles bancroft certain former current executives company case california voluntarily dismissed remaining complaint alleges violations securities laws companys disclosures related checkmate clinical trial lung cancer fully briefed motion dismiss pending court company intends defend vigorously litigation litigation acquisition celgene litigation february nine complaints filed celgene shareholders us district court district delaware us district court district new jersey us district court southern district new york court chancery state delaware seeking enjoin company 's proposed acquisition celgene complaints actions name defendants celgene members celgene 's board directors four complaints also name company burgundy merger sub inc whollyowned subsidiary company formed solely purpose completing pending acquisition celgene merged celgene upon completion acquisition defendants complaints naming company defendant three styled putative class actions plaintiffs allege violations various federal securities laws breaches fiduciary duties connection acquisition celgene company separately tenth complaint styled putative class action filed court chancery state delaware behalf company 's shareholders naming members company 's board directors defendants complaint alleges members company 's board directors breached fiduciary duties company shareholders failing disclose material information pending acquisition company burgundy merger sub celgene intend defend vigorously lawsuits acquisition flexus litigation february company acquired flexus including rights ido inhibitor september incyte corporation incyte sued flexus flexus 's founders flexus defendants superior court state delaware initial subsequent amended complaints incyte alleged claims flexus defendants among others misappropriation various trade secrets relating research development incyte 's ido inhibitor november following two ahalf week trial trade secrets jury superior court delaware returned defense verdict behalf flexus defendants incyte may appeal decision average wholesale price litigation company defendant qui tam whistleblower lawsuit us district court eastern district pennsylvania us government declined intervene complaint alleges company inaccurately reported average manufacturer prices centers medicare medicaid services lower owed similar claims filed companies court denied company 's motion dismiss november government investigations like pharmaceutical companies company certain subsidiaries subject extensive regulation national state local government agencies us countries bms operates result company time time subject various governmental inquiries investigations possible criminal charges substantial fines andor civil penalties could result government investigations environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties amount includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site note subsequent event january bms announced company entered definitive merger agreement bms acquire celgene terms agreement merger completed celgene shareholders receive one share bms common stock cash share celgene common stock held celgene shareholders also receive one tradeable contingent value right share celgene representing right receive cash subject achievement future regulatory milestones based closing price share bms common stock january recent trading day prior date announcement merger consideration represented approximately billion amount consideration received celgene stockholders fluctuate changes price shares bms common stock bms expects fund transaction combination existing cash new debt bms also expects enter accelerated share repurchase program approximately billion subject closing transaction market conditions board directors ' approval company expects transaction close end third quarter subject approval bristolmyers squibb celgene shareholders satisfaction customary closing conditions regulatory approvals note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earningsloss per share basica earningsloss per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets c longterm debt includes current portion following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrative license asset acquisition charges site exit costs research development lossgain equity investments provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement intangible asset impairment income net increasedecrease pretax income income taxes items income taxes attributed us tax reform income taxes increasedecrease net earnings first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement loss debt redemption income net increasedecrease pretax income income taxes items income taxes attributed us tax reform income taxes increasedecrease net earnings noncontrolling interest increasedecrease net earnings attributable bms specified items cost products sold accelerated depreciation asset impairment shutdown costs report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion financial statements audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion deloitte touche llp parsippany new jersey february served company 's auditor since item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined exchange act rules ae de end period covered based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting defined exchange act rule af supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report form k issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting item b information february company 's amendment registration statement form company 's pending acquisition celgene company disclosed starboard value lp sent notice nomination five directors company 's board directors company informed starboard value would review connection delivery notice starboard value requested meet company 's management pending discussions notice meetings kept confidential company 's management subsequently met starboard value multiple occasions vote potential changes companys board directors would come annual meeting shareholders date set time filing company 's shareholders expected vote proposed acquisition celgene april report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion internal control financial reporting audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso also audited accordance standards public company accounting oversight board united states pcaob consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement respect directors incorporated herein reference made part hereof response information required item b information required item respect executive officers included part ia reliance general instruction g instruction item b regulation sk incorporated herein reference made part hereof response information required item item executive compensation reference made proxy statement respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement respect auditor fees incorporated herein reference made part hereof response information required item part iv item